

# ChemMedChem

Supporting Information

## **Direct, Late-Stage Mono-*N*-arylation of Pentamidine: Method Development, Mechanistic Insight, and Expedient Access to Novel Antiparasitics against Diamidine-Resistant Parasites**

Jack Robertson, Marzuq A. Ungogo, Mustafa M. Aldfer, Leandro Lemgruber,  
Fergus S. McWhinnie, Bela E. Bode, Katherine L. Jones,\* Allan J. B. Watson,\*  
Harry P. de Koning,\* and Glenn A. Burley\*

## Contents

General information .....	3
Analytical HPLC .....	3
Purification of products .....	3
Analysis of products .....	4
Sample preparation for EPR spectroscopy .....	4
EPR measurements .....	5
X-Ray crystallography.....	5
Synthetic procedures .....	5
Chan-Lam procedure A .....	5
Chan-Lam procedure B .....	6
Chan-Lam procedure C.....	6
Chan-Lam procedure D .....	6
Reaction optimisation .....	6
Cu source/benzamidine eq trials .....	9
<b>Representative HPLC trace</b> .....	10
EPR results.....	10
Precipitate formation in reactions .....	12
Compound characterisations .....	12
Trypanosoma experiments .....	27
Resazurin-based drug sensitivity assay .....	27
Real-time measurement of fluorescence in parasites .....	28
Localisation of cellular targets using fluorescence microscopy.....	28
DNA UV Melt Analysis.....	29
NMR spectra .....	31
Crystallographic data tables.....	68
References .....	87

## General information

All reagents and solvents were obtained from commercial suppliers and were used without further purification. Pentamidine free base was synthesised from pentamidine isethionate by previously reported methods.<sup>1</sup> All glassware was oven-dried (150 °C) before use. All reactions were carried out under air. Reactions were monitored by thin layer chromatography (TLC) using Merck silica plates coated with fluorescent indicator UV254. TLC plates were analysed using 254/365 nm UV light or developed using potassium permanganate solution.

## Analytical HPLC

RP-HPLC was carried out using an Aeris 3.6 µm RP 250 x 4.6 mm widepore XB C18 column using a DIONEX 3000 series HPLC system equipped with a VWD3400 photodiode array detector. Analysis was performed using the method outlined below.

The absorbance was detected at 254 nm. Solvent A: Water (0.1 % TFA) Solvent B: Acetonitrile (0.1 % TFA). Flow rate 1.0 mL/min

**Table S1.** Analytical HPLC method A.

Time (min)	Solvent A	Solvent B
0	99 %	1 %
5	99 %	1%
30	50 %	50 %
35	50 %	50 %
40	99 %	1 %
45	99 %	1 %

## Purification of products

Normal-phase flash chromatography was carried out using ZEOprep 60 HYD 40-63 µm silica gel. Semi-preparative reversed-phase HPLC purification was carried out using a Phenomenex Clarity 5 µm RP 250 x 10.00 mm XB C18 column using a DIONEX 3000 series HPLC system equipped with a VWD3400 variable wavelength detector. Purifications were performed using 2 different systems using water (0.1% TFA) as Solvent A and acetonitrile (0.1% TFA) as Solvent B. The flow rate was set to 12.0 mL/min. RP-HPLC method A: The absorbance was detected at 254 nm. Solvent A: Water. Solvent B: Acetonitrile.

**Table S2.** RP-HPLC method A.

Time (min)	Solvent A	Solvent B
0	99 %	1 %
5	99 %	1%
45	50 %	50 %
50	50 %	50 %
55	99 %	1 %
60	99 %	1 %

RP-HPLC method **B**: The absorbance was detected at 254 nm. Solvent A: Water (0.1 % TFA). Solvent B: Acetonitrile (0.1 % TFA).

**Table S3.** RP-HPLC method B.

Time (min)	Solvent A	Solvent B
0	99 %	1 %
5	99 %	1%
25	50 %	50 %
30	50 %	50 %
35	10 %	90 %
40	10 %	90 %
45	99 %	1 %
50	99 %	1 %

### Analysis of products

Fourier-Transform Infra-Red (FTIR) spectra were obtained on a Shimadzu IRAffinity-1 spectrometer. <sup>19</sup>F NMR spectra were obtained on a Bruker AV 400 spectrometer at 376 MHz. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained on either a Bruker AV 400 at 400 MHz and 125 MHz, respectively, or Bruker DRX 500 at 500 MHz and 126 MHz, respectively. Chemical shifts are reported in ppm and coupling constants are reported in Hz. High-resolution mass spectra were recorded on an LTQ Orbitrap XL 1 mass spectrometer at the EPSRC UK National Mass Spectrometry Facility (Swansea) and a Thermo Exactive Orbitrap mass spectrometer at the University of St Andrews.

### Sample preparation for EPR spectroscopy

To 10 mL glass vials was added Cu(OAc)<sub>2</sub> (36.0 mg, 0.20 mmol) in *i*-PrOH (5.20 mL) to give a solution of 38.5 mM Cu(OAc)<sub>2</sub>. Appropriate additive quantities were used as detailed in Table S4.

**Table S4.** Samples prepared for EPR analysis.

Sample	Additive(s)	Mass, mmol
1	N/A	N/A
2	Benzamidine ( <b>1</b> )	48.0 mg, 0.40 mmol
3	K <sub>2</sub> CO <sub>3</sub>	55.0 mg, 0.40 mmol
4	PhB(OH) <sub>2</sub>	24.0 mg, 0.20 mmol
5	Benzamidine ( <b>1</b> ), K <sub>2</sub> CO <sub>3</sub> and PhB(OH) <sub>2</sub>	48.0 mg 0.40 mmol, 55.0 mg 0.40 mmol, 24.0 mg 0.20 mmol

### EPR measurements

The EPR spectra were obtained using a Bruker EMX 10/12 spectrometer operating at ~9.5 GHz with 100 kHz modulation. Measurements were performed using an ELEXSYS Super High Sensitivity Probehead (Bruker ER4122SHQE). The EPR spectra were recorded at 293 K using 10 mW microwave power, 2000 G field sweep centred at 3300 G with 1024 points resolution. A time constant and conversion time of 40.96 ms was used with a modulation amplitude of 0.8 mT and a microwave frequency of 9.766 GHz. EPR measurements carried out by Dr Bela Bode, University of St. Andrews.

### X-Ray crystallography

Data for compounds **4** and **10** were collected on Oxford Diffraction Gemini S or Xcalibur E instruments with graphite-monochromated Mo K $\alpha$  ( $\lambda = 0.71073$  Å) or Cu K $\alpha$  ( $\lambda = 1.54184$  Å) radiation. Data collection and processing used CrysAlisPro software. All structures were solved and refined to convergence on  $F^2$  for all independent reflections by the full-matrix least squares method using SHELXL-20144 or by the Gauss Newton algorithm using OLEX2.5. Crystal structure data for compounds **4** and **10** has been deposited at the Cambridge Crystallographic Data Centre under deposition numbers CCDC2101634 and CCDC 2101824, respectively

### Synthetic procedures

#### *Chan-Lam procedure A*

To an oven-dried microwave vial was added the corresponding amidine (1.00 mmol), boronic acid (2.00 mmol), Cu(OAc)<sub>2</sub> (181 mg, 1.00 mmol), NEt<sub>3</sub> (278  $\mu$ L, 2.00 mmol) and activated 4Å molecular sieves (1.00 g). Dichloromethane (3.25 mL) was then added to the solid mixture, sealed under air and stirred at room temperature for 16 h. The resulting suspension was filtered and the precipitate was washed with MeOH (3.00 mL). The resulting solution was concentrated *in vacuo* and the residue purified by silica gel chromatography.

### *Chan-Lam procedure B*

To an oven-dried microwave vial was added the corresponding amidine (0.40 mmol), boronic acid (0.20 mmol), Cu(OAc)<sub>2</sub> (36.0 mg, 0.20 mmol), K<sub>2</sub>CO<sub>3</sub> (55.0 mg, 0.40 mmol) and activated 4Å molecular sieves (200 mg). Isopropanol (0.65 mL) was then added to the solid mixture, sealed under air and stirred at room temperature for 2 h. The resulting suspension was filtered and the precipitate was washed with MeOH (5 × 1 mL). The resulting solution was concentrated *in vacuo* and the residue purified by either silica gel chromatography or RP-HPLC.

### *Chan-Lam procedure C*

To an oven-dried microwave vial was added the corresponding amidine (0.40 mmol), boronic acid (0.20 mmol), Cu(OAc)<sub>2</sub> (7.2 mg, 0.04 mmol), K<sub>2</sub>CO<sub>3</sub> (55 mg, 0.40 mmol) and activated 4Å molecular sieves (200 mg). Isopropanol (0.65 mL) was then added to the solid mixture, sealed under air and stirred in a sand bath at 50 °C for 24 h. The resulting suspension was filtered and the precipitate was washed with MeOH (5 × 1 mL). The resulting solution was concentrated *in vacuo* and the residue purified by either silica gel chromatography or RP-HPLC.

### *Chan-Lam procedure D*

To an oven dried microwave vial was added pentamidine free base (68.0 mg, 0.20 mmol), boronic acid (0.20 mmol), Cu(OAc)<sub>2</sub> (36.0 mg, 0.20 mmol) and activated 4Å molecular sieves (200 mg). MeOH (0.65 mL) was then added to the solid mixture before final addition of Et<sub>3</sub>N (56 µL, 0.40 mmol), sealed under air and stirred at room temperature for 16 h. The resulting suspension was filtered, and the precipitate was washed with MeOH (5 × 1.50 mL). The resulting solution was purified by semi-preparative RP-HPLC and lyophilised to afford the amidine product.

### *Reaction optimisation*

To an oven dried 5 mL microwave vial was added benzamidine **1** (0.40 mmol), phenyl boronic acid (0.20 mmol), Cu(OAc)<sub>2</sub> (as per Table S5), base or additive (0.40 mmol) and activated 4Å molecular sieves (200 mg). Solvent (0.65 mL) was then added to the solid mixture, sealed under air and stirred at room temperature for a defined time period. A 50 µL aliquot of the reaction was removed and diluted with 950 µL of MeOH. The resulting sample was then analysed by HPLC using analytical HPLC method A. Conversion was calculated using standard concentration curves of *N'*-phenylbenzimidamide (**2**) TFA salt and *N,N'*-diphenylbenzimidamide free base (**3**).

**Table S5.** Chan-Lam amidination optimisation of conditions.

Entry	Solvent	Reaction time	Additive	Cu(OAc) <sub>2</sub> eq	Reaction temp	<b>2</b> conv. <sup>a</sup>	<b>3</b> conv. <sup>a</sup>
-------	---------	---------------	----------	-------------------------	---------------	-----------------------------	-----------------------------

1	DCM	16 h	B(OH) <sub>3</sub>	1.0	rt	45%	11%
2	DCM	16 h	Et <sub>3</sub> N	1.0	rt	58% (59%) <sup>b</sup>	14%
3	MeOH	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	59%	2%
4	MeOH	16 h	K <sub>2</sub> CO <sub>3</sub>	0.5	rt	58%	2%
5	MeOH	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	80°C	36%	<1%
6	DMSO	16 h	Et <sub>3</sub> N	1.0	rt	47%	2%
7	DMSO	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	59%	<1%
8	MeCN	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	52%	8%
9	<i>i</i> -PrOH	16 h	B(OH) <sub>3</sub>	1.0	rt	38%	14%
<b>10</b>	<b><i>i</i>-PrOH</b>	<b>16 h</b>	<b>K<sub>2</sub>CO<sub>3</sub></b>	<b>1.0</b>	<b>rt</b>	<b>70%</b> <b>(72%)<sup>b</sup></b>	<b>4%</b>
11	<i>i</i> -PrOH	16 h	Et <sub>3</sub> N	1.0	rt	70%	6%
12	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	0.5	rt	7%	0%
13	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	80°C	61%	0%
14	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	1.2	rt	62%	4%
15	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	1.5	rt	60%	4%
16	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	2.0	rt	59%	4%
17	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	0-10°C	63%	5%
18	<i>i</i> -PrOH	16 h	Pyridine	1.0	rt	59%	3%
19	<i>i</i> -PrOH	8 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	63%	4%
20	<i>i</i> -PrOH	4 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	63%	3%
<b>21</b>	<b><i>i</i>-PrOH</b>	<b>2 h</b>	<b>K<sub>2</sub>CO<sub>3</sub></b>	<b>1.0</b>	<b>rt</b>	<b>76%</b> <b>(83%)<sup>b</sup></b>	<b>5%</b>
22	<i>i</i> -PrOH	1 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	58%	3%
23	<i>i</i> -PrOH	0.5 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	60%	3%
24	<i>i</i> -PrOH	48 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	69%	7%
25	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	0.5	rt	2%	0%
26	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub> + MnO <sub>2</sub> (3 eq.)	0.5	rt	2%	0%
27	<i>i</i> -PrOH	2 h	None	1.0	rt	3%	0%
28	<i>i</i> -PrOH:MeOH (3:1)	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	63%	<1%

29	<i>i</i> -PrOH:MeOH (1:1)	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	52%	<1%
30	<sup>t</sup> BuOH	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	49%	10%
31	H <sub>2</sub> O	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	<1%	0%
32	DMF	2 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	31%	2%
33	DMF	16 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	55%	<1%
34	DCE	2 h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	40%	3%
35	MeOH	2 h	Et <sub>3</sub> N	1.0	rt	51%	<1%
36	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	0.5	50°C	56%	--
37	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	0.2	50°C	62%	--
38	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	0.1	50°C	18%	--
39	<i>i</i> -PrOH	24 h	K <sub>2</sub> CO <sub>3</sub>	0.5	50°C	76%	2%
<b>40</b>	<b><i>i</i>-PrOH</b>	<b>24 h</b>	<b>K<sub>2</sub>CO<sub>3</sub></b>	<b>0.2</b>	<b>50°C</b>	<b>81%<sup>b</sup></b>	--
41	<i>i</i> -PrOH	24 h	K <sub>2</sub> CO <sub>3</sub>	0.1	50°C	64%	--
42	DMF	24 h	NaOPiv	0.5	50°C	72% <sup>c,d</sup>	7% <sup>c,d</sup>
43	DMF	24 h	NaOPiv	0.2	50°C	81% <sup>c,d</sup>	2% <sup>c,d</sup>
44	DMF	2 h	NaOPiv	0.2	50°C	54% <sup>c,d</sup>	--
45	<i>i</i> -PrOH	2 h	NaOPiv	1.0	rt	66%	4%
46	<i>i</i> -PrOH	2 h	NaOPiv	0.5	rt	64%	2%
47	<i>i</i> -PrOH	2 h	NaOPiv	0.2	rt	14%	--
48	<i>i</i> -PrOH	2 h	NaOPiv	1.0	50°C	71%	5%
49	<i>i</i> -PrOH	2 h	NaOPiv	0.5	50°C	68%	2%
50	<i>i</i> -PrOH	2 h	NaOPiv	0.2	50°C	47%	--
51	<i>i</i> -PrOH	24 h	NaOPiv	1.0	50°C	63%	5%
52	<i>i</i> -PrOH	24 h	NaOPiv	0.5	50°C	69%	3%
53	<i>i</i> -PrOH	24 h	NaOPiv	0.2	50°C	47%	--
54	DCM	16h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	40%	8%
55	MeOH	16h	K <sub>2</sub> CO <sub>3</sub>	1.0	rt	59%	2%

a) Conversion calculated using standard calibration curve b) Isolated yield on 1.00 mmol scale c) 0.25 M reaction concentration. d) 1:PhB(OH)<sub>2</sub>=1:1.2 used.



### Cu source/benzamidine eq trials


To an oven dried 5 mL microwave vial was added benzamidine **1** (as per Table S6), phenyl boronic acid (0.20 mmol), Cu source (0.20 mmol), base or additive (0.40 mmol) and activated 4Å molecular sieves (200 mg). Solvent (0.65 mL) was then added to the solid mixture, sealed under air and stirred at room temperature for desired time. A 50 µL aliquot of the reaction was removed and diluted with 950 µL of MeOH. The resulting sample was then analysed by HPLC using analytical HPLC method A. Conversion was calculated using standard concentration curves of *N*-phenylbenzimidamide (**2**) TFA salt and *N,N'*-diphenylbenzimidamide (**3**).

**Table S6.** Reaction optimisation using altering Cu source and eq of benzamidine.

Entry	Solvent	Reaction time	Additive	Cu source	<b>1</b> eq.	<b>2</b> conv. <sup>a</sup>	<b>3</b> conv. <sup>a</sup>
1	MeOH	16 h	K <sub>2</sub> CO <sub>3</sub>	Cu(OAc) <sub>2</sub>	1.5	49%	2%
2	MeOH	16 h	K <sub>2</sub> CO <sub>3</sub>	Cu(OAc) <sub>2</sub>	1.2	43%	2%
3	DCM	16 h	B(OH) <sub>3</sub>	Cu(OAc) <sub>2</sub>	2.0	26% <sup>b</sup>	5% <sup>b</sup>
4	<i>i</i> -PrOH	16 h	None	Cu <sub>2</sub> (OH) <sub>2</sub> CO <sub>3</sub>	2.0	0%	0%
5	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	Cu(OAc) <sub>2</sub>	1.5	63%	5%
6	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	Cu <sub>2</sub> (OH) <sub>2</sub> CO <sub>3</sub>	2.0	<1%	0%
7	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	Cu(OAc) <sub>2</sub>	1.0	46%	6%
8	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	[Cu(MeCN)]PF <sub>6</sub> (0.5 eq)	2.0	5%	0%
9	<i>i</i> -PrOH	16 h	K <sub>2</sub> CO <sub>3</sub>	[Cu(MeCN)]PF <sub>6</sub>	2.0	35%	3%
10	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	CuOAc	2.0	2%	0%
11	MeOH	2 h	K <sub>2</sub> CO <sub>3</sub>	CuOAc	2.0	14%	0%
12	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub> + KOAc  (1 eq)	CuOAc	2.0	<1%	0%
13	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	Complex <b>4</b>	2.0	2%	0%
14	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	Complex <b>4</b> (0.5 eq), Cu(OAc) <sub>2</sub> (0.5 eq)	2.0	2%	0%
15	<i>i</i> -PrOH	2 h	K <sub>2</sub> CO <sub>3</sub>	Complex <b>4</b>	2.0	18% <sup>c</sup>	0%
16	<i>i</i> -PrOH	24 h	K <sub>2</sub> CO <sub>3</sub>	Complex <b>4</b>	2.0	61% <sup>c</sup>	0%
17	DCM	16 h	Et <sub>3</sub> N	Cu(OAc) <sub>2</sub>	1.0	8% <sup>b,d</sup>	74% <sup>b,d</sup>

a) Conversion calculated using standard calibration curve b) Isolated yield on 1.00 mmol scale c) Reaction heated to 50 °C. d) 1:PhB(OH)<sub>2</sub>=1:2.


## Representative HPLC trace



**Figure S1.** HPLC trace (Table S4, entry 21) showing starting material **1** (7.2 min), major product **2** (15.4 min) and minor product **3** (22.9 min).

## EPR results


Results detailed in Figure S2 illustrate de-nucleation of the  $\text{Cu}(\text{OAc})_2$  dimer in the presence of benzimidine (green) to give a mononuclear  $\text{Cu}^{\text{II}}$  signal.  $\text{Cu}(\text{OAc})_2$  gives no signal (black) and addition of  $\text{K}_2\text{CO}_3$  (red) or  $\text{PhB}(\text{OH})_2$  (blue) provides no de-nucleation. Mononuclear  $\text{Cu}^{\text{II}}$  signal again observed in the presence of amidine with  $\text{K}_2\text{CO}_3$  and phenyl boronic acid (purple). Note precipitate formation for the sample containing all reagents shows a less intense signal (purple).



**Figure S2.** EPR spectra showing the de-nucleation of  $\text{Cu(OAc)}_2$  with the different substrate combinations.

## Precipitate formation in reactions


Images of precipitate formed during substoichiometric reactions.



**Figure S3.** Purple precipitate formed during reactions using substoichiometric copper. Conditions:  $\text{Cu}(\text{OAc})_2$  (50 mol%),  $\text{K}_2\text{CO}_3$  (2 equiv.), 4 Å MS, *i*-PrOH, RT, 2 h.

## Compound characterisations

(*Z*)-*N'*-phenylbenzimidamide (**2**)



Chan-Lam procedure A (1.00 mmol scale boronic acid). Purification was carried out using a gradient of 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording a white powder (8 mg, 9 %).

Chan-Lam procedure B (1.00 mmol scale boronic acid). Purification was carried out using a gradient of 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording a white powder (162 mg, 83 %).

Chan-Lam procedure C (1.00 mmol scale boronic acid). Purification was carried out using a gradient of 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording a colourless solid (159 mg, 81 %).

**mp** 108-112 °C.


**<sup>1</sup>H NMR** (500 MHz,  $\text{CDCl}_3$ ):  $\delta$ /ppm: 7.87 (d, 2H,  $J = 6.9$  Hz,  $\text{N}=\text{C}_q-\text{C}_q-\text{CH} \times 2$ ), 7.43-7.51 (m, 3H,  $\text{N}=\text{C}_q-\text{C}_q-\text{CH}-\text{CH} \times 2-\text{CH}$ ), 7.35-7.39 (m, 2H,  $\text{N}-\text{C}_q-\text{CH}-\text{CH} \times 2$ ), 7.05-7.09 (m, 1H,  $\text{N}-\text{C}_q-\text{CH}-\text{CH}-\text{CH}$ ), 7.00-7.02 (m, 2H,  $\text{N}-\text{C}_q-\text{CH} \times 2$ ), 4.85 (br s, 2H,  $\text{NH}_2$ ).

$^{13}\text{C}\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta$ /ppm: 154.2 ( $\text{C}_q$ ), 151.1( $\text{C}_q$ ), 136.4 ( $\text{C}_q$ ), 130.5 ( $\text{C-H}$ ), 129.7 ( $2 \times \text{C-H}$ ), 128.4 ( $2 \times \text{C-H}$ ), 127.5 ( $2 \times \text{C-H}$ ), 122.3 ( $\text{C-H}$ ), 122.0 ( $2 \times \text{C-H}$ ).

**IR (neat):**  $\nu_{\text{max}}/\text{cm}^{-1}$ : 3565 (N-H stretch), 3344 (N-H stretch), 3051 (C-H stretch), 3040 (C-H stretch), 1615 (C=N stretch), 1589 (C=C stretch), 1569 (C=C stretch).

**HRMS (ESI):** Calc. for  $\text{C}_{13}\text{H}_{13}\text{N}_2^+$ . Theoretical: 197.1073 Observed: 197.1072.

(*Z*)-*N,N'*-diphenylbenzimidamide (**3**)



Chan-Lam procedure A (1.00 mmol scale boronic acid). Purification was carried out using a gradient of 0% to 60% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier affording a colourless solid (201 mg, 74 %).

Chan-Lam procedure B (1.00 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording a colourless solid (8 mg, 3%).

**mp** 140-143 °C.


$^1\text{H}$  NMR (500 MHz,  $\text{DMSO-d}_6$ ):  $\delta$ /ppm: 9.18 (br s, 1H, NH), 7.88 (d, 2H,  $J = 7.3$  Hz,  $\text{N}=\text{C}_q\text{-C}_q\text{-CH} \times 2$ ), 7.26-7.33 (m, 7H,  $7 \times \text{CH}$ ) 7.96-7.06 (m, 3H,  $3 \times \text{CH}$ ), 6.73-6.77 (m, 1H,  $\text{N-C}_q\text{-CH-CH-CH}$ ), 6.58 (d, 2H,  $J = 7.1$  Hz,  $\text{N-C}_q\text{-CH} \times 2$ ).

$^{13}\text{C}\{^1\text{H}\}$  NMR (125 MHz,  $\text{DMSO-d}_6$ ):  $\delta$ /ppm: 154.2 ( $\text{C}_q$ ), 150.6 ( $\text{C}_q$ ), 141.3 ( $\text{C}_q$ ), 134.7 ( $\text{C}_q$ ), 128.9 ( $\text{C-H}$ ), 128.9 ( $\text{C-H}$ ), 128.8 ( $2 \times \text{C-H}$ ), 128.3 ( $2 \times \text{C-H}$ ), 127.9 ( $2 \times \text{C-H}$ ), 122.2 ( $2 \times \text{C-H}$ ), 121.8 ( $2 \times \text{C-H}$ ), 120.9 ( $\text{C-H}$ ), 119.5 ( $2 \times \text{C-H}$ ).

**IR (neat):**  $\nu_{\text{max}}/\text{cm}^{-1}$ : 3290 (N-H stretch), 3053 (C-H stretch), 3025 (C-H stretch), 1627 (C=N stretch), 1587 (C=C stretch), 1578 (C=C stretch), 1528 (C=C stretch).

**HRMS (ESI):** Calc. for  $\text{C}_{19}\text{H}_{17}\text{N}_2^+$ . Theoretical: 273.1386 Observed: 273.1387.

(*Z*)-*N'*-(4-fluorophenyl)benzimidamide (**7**)



Chan-Lam procedure B (0.20 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording a white powder (27 mg, 63%)

Chan-Lam procedure C (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording a colourless solid (61 mg, 71%).

**mp** 113-117 °C.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.84 (br s, 2H, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.43-7.50 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH), 7.03-7.06 (m, 2H, F-C<sub>q</sub>-CH × 2), 6.92-6.95 (m, 2H, F-C<sub>q</sub>-CH-CH × 2), 4.84 (br s, 2H, NH<sub>2</sub>).


**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm: 158.6 (d, *J* = 241.4 Hz, C-F), 154.9 (C<sub>q</sub>), 144.9 (C<sub>q</sub>), 135.0 (C<sub>q</sub>), 130.2 (C-H), 128.1 (2 × C-H), 126.3 (2 × C-H), 122.3 (d, *J* = 7.9 Hz, 2 × C-H), 115.6 (d, *J* = 22.2 Hz, 2 × C-H).

**<sup>19</sup>F{<sup>1</sup>H} NMR** (470 MHz, CDCl<sub>3</sub>): δ/ppm: -121.3.

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3465 (N-H stretch), 3335 (N-H stretch), 3056 (C-H stretch), 1613 (C=N stretch), 1600 (C=C stretch), 1569 (C=C stretch), 1498 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>F<sup>+</sup>. Theoretical: 215.0979 Observed: 215.0978.

(*Z*)-*N'*-(4-(methylthio)phenyl)benzimidamide (**8**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 40% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a colourless solid (69 mg, 71%).

Chan-Lam procedure C (0.04 mmol scale boronic acid). Purification was carried out using a gradient 0% to 40% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a colourless solid (65 mg, 67%).

**mp** 123-127 °C.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.82 (d, 2H, *J* = 6.8, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.42-7.49 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH), 7.28 (d, 2H, *J* = 8.4 Hz, S-C<sub>q</sub>-CH × 2), 6.93 (d, 2H, *J* = 8.4 Hz, S-C<sub>q</sub>-CH-CH × 2), 4.85 (br s, 2H, NH<sub>2</sub>) 2.48 (s, 3H, S-CH<sub>3</sub>).

**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ 155.3 (C<sub>q</sub>), 147.2 (C<sub>q</sub>), 135.5 (C<sub>q</sub>), 131.9 (C<sub>q</sub>), 130.7 (C-H), 129.0 (2 × C-H), 128.6 (2 × C-H), 126.8 (2 × C-H), 122.4 (2 × C-H), 17.0 (S-CH<sub>3</sub>).

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3465 (N-H stretch), 3324 (N-H stretch), 2915 (C-H alkyl stretch), 1621 (C=N stretch), 1600 (C=C stretch), 1589 (C=C stretch), 1558 9C=C stretch).

**HRMS (ESI):** Calc. for C<sub>14</sub>H<sub>15</sub>N<sub>2</sub>S<sup>+</sup>. Theoretical: 243.0950 Observed: 243.0945.

(*Z*)-*N'*-(4-(tert-butyl)phenyl)benzimidamide (**9**)



Chan-Lam procedure B (0.20 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording an off-white powder (41 mg, 82%).

**mp** 153-155 °C.


**<sup>1</sup>H NMR** (500MHz, CDCl<sub>3</sub>): δ/ppm: 7.86 (d, 2H, *J* = 5.0 Hz, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.42-7.49 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH) 7.35 (d, 2H, *J* = 8.5 Hz, <sup>t</sup>Bu-C<sub>q</sub>-CH × 2), 6.92 (d, 2H, *J* = 8.5 Hz, <sup>t</sup>Bu-C<sub>q</sub>-CH-CH × 2), 4.92 (br s, 2H, NH<sub>2</sub>), 1.32 (s, 9H, CH<sub>3</sub> × 3).

**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ /ppm: 154.9 (C<sub>q</sub>), 145.5 (C<sub>q</sub>), 135.1 (C<sub>q</sub>), 130.1 (C-H), 128.1 (2 × C-H), 126.4 (2 × C-H), 125.8 (2 × C-H), 122.3 (C<sub>q</sub>), 120.7 (2 × C-H), 33.8 (C<sub>q</sub>), 30.9 (3 × CH<sub>3</sub>).

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3439 (N-H stretch), 3121 (N-H stretch), 3054 (C-H stretch), 2898 (C-H alkyl stretch), 2863 (C-H alkyl stretch), 1632 (C=N stretch), 1597 (C=C stretch), 1571 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub><sup>+</sup>. Theoretical : 253.1699 Observed : 253.1701.

(*Z*)-*N'*-(4-(trifluoromethyl)phenyl)benzimidamide (**10**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a colourless solid (68 mg, 64%).

**mp** 143-145 °C.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.86 (br s, 2H, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.61 (d, 2H, *J* = 8.2 Hz, F<sub>3</sub>C-C<sub>q</sub>-CH × 2), 7.44-7.53 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH), 7.08 (d, 2H, *J* = 8.2, F<sub>3</sub>C-C<sub>q</sub>-CH-CH × 2), 4.86 (br s, 2H, NH<sub>2</sub>).


**<sup>13</sup>C{<sup>1</sup>H} NMR** (101 MHz, CDCl<sub>3</sub>): δ/ppm: 155.1 (C<sub>q</sub>), 152.1 (C<sub>q</sub>), 134.4 (C<sub>q</sub>), 130.6 (C-H), 128.2 (2 × C-H), 126.4 (2 × C-H), 126.2 (q, *J* = 3.5 Hz, 2 × C-H), 124.7 (q, *J* = 32.9, C<sub>q</sub>), 124.0 (q, *J* = 270.6 Hz, CF<sub>3</sub>), 121.5 (2 × C-H).

**<sup>19</sup>F{<sup>1</sup>H} NMR** (376 MHz, CDCl<sub>3</sub>): δ/ppm: -61.8.

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3463 (N-H stretch), 3330 (N-H stretch), 3049 (C-H stretch), 1619 (C=N stretch), 1599 (C=C stretch), 1573 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>14</sub>H<sub>11</sub>N<sub>2</sub>F<sub>3</sub><sup>+</sup>. Theoretical: 265.0947 Observed: 265.0947.

(*Z*)-*N'*-(*m*-tolyl)benzimidamide (**11**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a colourless solid (51 mg, 61%).

**mp** 98-102 °C.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.86 (d, 2H, *J* = 7.0 Hz, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.42-7.49 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH) 7.22-7.25 (m, 1H, N-C<sub>q</sub>-CH-CH), 6.88 (d, 1H, *J* = 7.5 Hz, N-C<sub>q</sub>-CH-CH-CH), 6.83 (s, 1H, N-C<sub>q</sub>-CH-C<sub>q</sub>-CH<sub>3</sub>), 6.79 (d, 1H, *J* = 7.9 Hz, N-C<sub>q</sub>-CH-CH) 4.84 (br s, 2H, NH<sub>2</sub>), 2.35 (s, 3H, CH<sub>3</sub>).

**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm 154.4 (C<sub>q</sub>), 148.9 (C<sub>q</sub>), 138.8 (C<sub>q</sub>), 135.3 (C<sub>q</sub>), 130.1 (C-H), 128.8 (C-H), 128.0 (2 × C-H), 126.3 (2 × C-H), 123.4 (C-H), 121.8 (C-H), 118.1 (C-H), 21.0 (CH<sub>3</sub>).

**IR (neat):**  $\nu_{\max}/\text{cm}^{-1}$ : 3434 (N-H stretch), 3285 (N-H stretch), 3127 (C-H stretch), 1625 (C=N stretch), 1604 (C=C stretch), 1591 (C=C stretch), 1571 (C=C stretch).

**HRMS (ESI):** Calc. for  $\text{C}_{14}\text{H}_{15}\text{N}_2^+$ . Theoretical: 211.1230 Observed: 211.1224.

(Z)-N'-([1,1'-biphenyl]-4-yl)benzimidamide (**12**)



Chan-Lam procedure B (1.00 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording an off-white powder (188 mg, 69%).

**mp** 173-177 °C.


**$^1\text{H}$  NMR** (500 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 7.88 (d, 2H,  $J = 5.8$  Hz,  $\text{N}=\text{C}_q\text{-C}_q\text{-CH} \times 2$ ), 7.60-7.62 (m, 4H,  $4 \times \text{CH}$ ), 7.42-7.51 (m, 5H,  $5 \times \text{CH}$ ), 7.31-7.34 (m, 1H,  $\text{N-C}_q\text{-CH-CH-C}_q\text{-CH-CH-CH}$ ), 7.07 (d, 2H,  $J = 8.4$  Hz,  $2 \times \text{CH}$ ), 4.91 (br s, 2H,  $\text{NH}_2$ ).

**$^{13}\text{C}\{^1\text{H}\}$  NMR** (125 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 155.0 ( $\text{C}_q$ ), 148.9 ( $\text{C}_q$ ), 141.0 ( $\text{C}_q$ ), 135.9 ( $\text{C}_q$ ), 135.7 ( $\text{C}_q$ ), 130.7 (C-H), 128.8 ( $2 \times \text{C-H}$ ), 128.6 ( $2 \times \text{C-H}$ ), 128.2 ( $2 \times \text{C-H}$ ), 126.9 (C-H), 126.8 ( $2 \times \text{C-H}$ ), 126.7 ( $2 \times \text{C-H}$ ), 122.1 ( $2 \times \text{C-H}$ ).

**IR (neat):**  $\nu_{\max}/\text{cm}^{-1}$ : 3463 (N-H stretch), 3344 (N-H stretch), 3056 (C-H stretch), 3028 (C-H stretch), 1610 (C=N stretch), 1589 (C=C stretch), 1569 (C=C stretch).

**HRMS (ESI):** Calc. for  $\text{C}_{19}\text{H}_{17}\text{N}_2^+$ . Theoretical: 273.1386 Observed: 273.1386.

(Z)-N'-(*o*-tolyl)benzimidamide (**13**)



Chan-Lam procedure B (0.20 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording an off-white powder (17 mg, 40%).

Chan-Lam procedure C (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording an off-white powder (40 mg, 48%).

**mp** 115-118 °C.

**$^1\text{H}$  NMR** (500 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 7.89 (br s, 2H,  $\text{N}=\text{C}_q\text{-C}_q\text{-CH} \times 2$ ), 7.43-7.50 (m, 3H,  $\text{N}=\text{C}_q\text{-C}_q\text{-CH-CH} \times 2\text{-CH}$ ), 7.22 (d, 1H,  $J = 7.4$ ,  $\text{N-C}_q\text{-C}_q\text{-CH}$ ), 7.16-7.19 (m, 1H,  $\text{N-C}_q\text{-CH-CH}$ ), 6.97-7.00 (m, 1H,  $\text{N-C}_q\text{-C}_q\text{-CH-CH}$ ), 6.88 (d, 1H,  $J = 7.4$  Hz,  $\text{N-C}_q\text{-CH}$ ), 4.71 (br s, 2H,  $\text{NH}_2$ ), 2.22 (s, 3H,  $\text{CH}_3$ ).


**$^{13}\text{C}\{^1\text{H}\}$  NMR** (125 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 153.0 ( $\text{C}_q$ ), 147.0 ( $\text{C}_q$ ), 134.7 ( $\text{C}_q$ ), 129.8 (C-H), 129.7 (C-H), 128.7 ( $\text{C}_q$ ), 127.6 ( $2 \times \text{C-H}$ ), 125.9 ( $2 \times \text{C-H}$ ), 125.8 (C-H), 122.3 (C-H), 120.2 (C-H), 16.7 ( $\text{CH}_3$ ).

**IR (neat):**  $\nu_{\max}/\text{cm}^{-1}$ : 3436 (N-H stretch), 3162 (N-H stretch), 3056 (C-H stretch), 2917 (C-H alkyl stretch), 1630 (C=N stretch), 1595 (C=C stretch), 1563 (C=N stretch).



**HRMS (ESI):** Calc. for  $C_{14}H_{15}N_2^+$ . Theoretical: 211.1230 Observed: 211.1229.

(Z)-N'-(2-methoxyphenyl)benzimidamide (**14**)



Chan-Lam procedure B (0.20 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $Et_3N$  modifier, affording an off-white powder (39 mg, 42%).

**mp** 109-113 °C.


**$^1H$  NMR** (500 MHz,  $CDCl_3$ ):  $\delta$ /ppm: 7.86 (d, 2H,  $J = 6.2$  Hz,  $N=C_q-C_q-CH \times 2$ ), 7.42-7.50 (m, 3H,  $N=C_q-C_q-CH-CH \times 2-CH$ ), 7.19 (br s, 1H,  $N-C_q-CH$ ), 7.03-7.08 (m, 1H,  $N-C_q-C_q-CH-CH$ ), 6.94-6.99 (m, 2H,  $N-C_q-CH-CH$ ,  $N-C_q-C_q-CH$ ), 4.72 (br s, 2H,  $NH_2$ ), 3.83 (s, 3H,  $O-CH_3$ ).

**$^{13}C\{^1H\}$  NMR** (125 MHz,  $CDCl_3$ ):  $\delta$ /ppm: 154.0 ( $C_q$ ), 151.3 ( $C_q$ ), 139.8 ( $C_q$ ), 136.3( $C_q$ ), 130.4 ( $C-H$ ), 128.4 ( $2 \times C-H$ ), 127.6 ( $2 \times C-H$ ), 123.2 ( $C-H$ ), 122.9 ( $C-H$ ), 121.5 ( $C-H$ ), 112.8 ( $C-H$ ), 55.8 ( $O-CH_3$ ).

**IR (neat)  $\nu_{max}$  (neat):** 3434 (N-H stretch), 3294 (N-H stretch), 3054 (C-H stretch), 2826 (C-H alkyl stretch), 1640 (C=N stretch), 1569 (C=C stretch).

**HRMS (ESI):**  $C_{14}H_{15}N_2O^+$ . Theoretical: 227.1179 Observed: 227.1171.

(Z)-N'-(pyridin-3-yl)benzimidamide trifluoroacetate (**15**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using RP-HPLC method A, affording a white amorphous solid (47 mg, 38%).

**$^1H$  NMR** (500 MHz,  $DMSO-d_6$ ):  $\delta$ /ppm: 8.19 (s, 1H,  $N=CH-CH$ ), 8.13, (s, 1H,  $N=CH-C_q$ ), 7.97 (d, 2H,  $J = 6.9$  Hz,  $N=C_q-C_q-CH \times 2$ ), 7.45-7.49 (m, 3H,  $N=C_q-C_q-CH-CH \times 2-CH$ ), 7.26-7.49 (m, 2H,  $N-C_q-CH-CH$ ), 6.59 (br s, 2H,  $NH_2$ ).


**$^{13}C\{^1H\}$  NMR** (125 MHz,  $DMSO-d_6$ ):  $\delta$ /ppm: 155.2 ( $C_q$ ), 146.5 ( $C-H$ ), 143.6 ( $C_q$ ), 142.8 ( $C-H$ ), 135.5 ( $C_q$ ), 130.3 ( $C-H$ ), 128.7 ( $C-H$ ), 128.0 ( $2 \times C-H$ ), 127.1 ( $2 \times C-H$ ), 123.9 ( $C-H$ ).

**$^{19}F\{^1H\}$  NMR** (470 MHz,  $DMSO-d_6$ ):  $\delta$ /ppm: -73.5.

**IR (neat):  $\nu_{max}/cm^{-1}$ :** 3376 (N-H stretch), 3318 (N-H stretch), 3185 (C-H stretch), 1647 (C=N stretch), 1610 (C=N stretch), 1573 (C=C stretch).

**HRMS (ESI):** Calc. for  $C_{12}H_{12}N_3^+$ . Theoretical: 198.1026 Observed: 198.1022.

(Z)-N'-(3-fluoro-4-methoxyphenyl)benzimidamide (**16**)



Chan-Lam procedure B (0.20 mmol scale boronic acid). Purification was carried out using a gradient

0% to 50% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a colourless solid (67 mg, 68%).

**mp** 119-123 °C.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.83 (br s, 2H, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.43-7.50 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH), 6.95 (m, 1H, N-C<sub>q</sub>-CH-CH), 6.78 (d, 1H, *J* = 12.4 Hz, N-C<sub>q</sub>-CH-CF), 6.70 (d, 1H, *J* = 8.5 Hz N-C<sub>q</sub>-CH-CH), 4.91 (br s, 2H, NH<sub>2</sub>) 3.88 (s, 3H, O-CH<sub>3</sub>).


**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm: 155.7 (C<sub>q</sub>), 153.0 (d, *J* = 246.8 Hz, C-F), 143.5 (d, *J* = 10.8, C<sub>q</sub>), 143.0 (C<sub>q</sub>), 135.5 (C<sub>q</sub>), 130.7 (C-H), 128.6 (2 × C-H), 126.8 (2 × C-H), 117.1 (C-H), 114.7 (d, *J* = 2.1 Hz, C-H), 110.2 (d, *J* = 18.9 Hz, C-H), 56.7 (O-CH<sub>3</sub>).

**<sup>19</sup>F{<sup>1</sup>H} NMR** (376 MHz, CDCl<sub>3</sub>): δ/ppm: -133.5.

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3458 (N-H stretch), 3287 (N-H stretch), 3135 (C-H stretch), 3017 (C-H stretch), 2842 (C-H alkyl stretch), 1627 (C=N stretch), 1593 (C=C stretch), 1569 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>14</sub>H<sub>14</sub>N<sub>2</sub>FO<sup>+</sup>. Theoretical: 245.1085 Observed: 245.1078.

(*Z*)-*N'*-(3-methoxyphenyl)benzimidamide (**17**)



Chan-Lam procedure B (0.20 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a colourless solid (28 mg, 62%).

**mp** 108-112 °C.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.86 (d, 2H, *J* = 5.4 Hz, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.43-7.50 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH) 7.24-7.27 (m, 1H, , N-C<sub>q</sub>-CH-CH), 6.63 (dd, 1H, *J* = 8.4 Hz, 2.3 Hz, N-C<sub>q</sub>-CH-CH-CH), 6.56-6.59 (m, 2H, N-C<sub>q</sub>-CH × 2,) 4.89 (br s, 2H, NH<sub>2</sub>), 3.80 (s, 3H, CH<sub>3</sub>).

**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm: 160.3 (C<sub>q</sub>), 154.6 (C<sub>q</sub>), 150.4 (C<sub>q</sub>), 135.11 (C<sub>q</sub>), 130.2 (C-H), 129.8 (C-H), 128.1 (2 × C-H), 126.3 (2 × C-H), 113.4 (C-H), 108.6 (C-H), 106.7 (C-H), 54.7 (O-CH<sub>3</sub>).

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3432 (N-H stretch), 3279 (N-H stretch), 3095 (C-H stretch), 2934 (C-H alkyl stretch), 2831 (C-H alkyl stretch), 1636 (C=N stretch), 1587 (C=C stretch), 1573 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>14</sub>H<sub>15</sub>N<sub>2</sub>O<sup>+</sup>. Theoretical: 227.1178 Observed: 227.1179.

(*Z*)-*N'*-(4-methoxy-3,5-dimethylphenyl)benzimidamide (**18**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 30% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording an off-white powder. (85 mg, 83%).

**mp** 140-143 °C.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.84 (d, 2H, *J* = 6.9 Hz, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.41-7.47 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH), 6.64 (s, 2H, N-C<sub>q</sub>-CH × 2), 4.86 (br s, 2H, NH<sub>2</sub>), 3.72 (s, 3H, O-CH<sub>3</sub>), 2.27 (s, 6H, C<sub>q</sub>-CH<sub>3</sub> × 2).

**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm: 154.2 (C<sub>q</sub>), 152.3 (C<sub>q</sub>), 144.7 (C<sub>q</sub>), 135.5 (C<sub>q</sub>), 131.3 (C<sub>q</sub>), 130.0 (C-H), 128.0 (2 × C-H), 126.2 (2 × C-H), 121.0 (2 × C-H), 59.3 (O-CH<sub>3</sub>), 15.7 (2 × CH<sub>3</sub>).

**IR (neat) v<sub>max</sub>/cm<sup>-1</sup>:** 3413 (N-H stretch), 3341 (N-H stretch), 3207 (C-H stretch), 2930 (C-H alkyl stretch), 2921 (C-H alkyl stretch), 2854 (C-H alkyl stretch), 1638 (C=N stretch), 1569 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>16</sub>H<sub>19</sub>N<sub>2</sub>O<sup>+</sup>. Theoretical: 255.1492 Observed: 255.1487.

(*Z*)-*N'*-(3,4,5-trifluorophenyl)benzimidamide (**19**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 30% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording an off-white powder (57 mg, 57%).

**mp** 108-110 °C.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.79 (br s, 2H, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.50-7.53 (m, 1H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH-CH), 7.44-7.47 (m, 2H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2), 6.58-6.62 (m, 2H, N-C<sub>q</sub>-CH × 2), 5.99 (br s, 2H, NH<sub>2</sub>).


**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm: 154.5 (C<sub>q</sub>), 150.9 (ddd, *J* = 248.4 Hz, 10.5 Hz, 4.9 Hz, 2 × C-F), 144.6 (ddd, *J* = 13.4 Hz, 9.1 Hz, 3.6 Hz, C-F), 135.9 (t, *J* = 15.8 Hz, C<sub>q</sub>), 134.0 (C<sub>q</sub>), 130.1 (C-H), 127.7 (2 × C-H), 125.7 (2 × C-H), 104.8 (dd, *J* = 16.7 Hz, 4.9 Hz, 2 × C-H).

**<sup>19</sup>F{<sup>1</sup>H} NMR** (470 MHz, CDCl<sub>3</sub>): δ/ppm: -133.9 (d, *J* = 19.2 Hz), -168.2 (t, *J* = 19.2 Hz).

**IR (neat): v<sub>max</sub>/cm<sup>-1</sup>:** 3426 (N-H stretch), 3277 (N-H stretch), 3116 (C-H stretch), 1636 (C=N stretch), 1574 (C=C stretch), 1517 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>13</sub>H<sub>10</sub>F<sub>3</sub>N<sub>2</sub><sup>+</sup>. Theoretical: 251.0791 Observed: 251.0782.

(*Z*)-*N'*-((*E*)-styryl)benzimidamide (**20**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a pale-yellow powder (31 mg, 35 %).

**mp** 117-121°C

**<sup>1</sup>H NMR** (500 MHz, DMSO-*d*<sub>6</sub>): δ/ppm: 7.91 (d, 2H, *J* = 6.9 Hz, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.86 (d, 1H, *J* = 13.4 Hz, N-CH=CH-C<sub>q</sub>), 7.44-7.46 (m, 2H, N-CH=CH-C<sub>q</sub>-CH × 2), 7.38-7.43 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH), 7.24-7.27 (m, 2H, N-CH=CH-C<sub>q</sub>-CH-CH × 2), 7.07-7.13 (m, 3H, NH<sub>2</sub>, CH=CH-C<sub>q</sub>-CH-


CH-CH), 6.32 (d, 1H,  $J = 13.4$  Hz, N-CH=CH-C<sub>q</sub>).

<sup>13</sup>C{<sup>1</sup>H} NMR (125 MHz, DMSO-d<sub>6</sub>):  $\delta$ /ppm: 155.6 (C<sub>q</sub>), 138.9 (C<sub>q</sub>), 136.6 (C<sub>q</sub>), 136.0 (C-H), 130.4 (C-H), 128.9 (2 × C-H), 128.5 (2 × C-H), 127.4 (2 × C-H), 126.0 (C-H), 125.9 (2 × C-H), 121.2 (C-H).

IR (neat):  $\nu_{\max}/\text{cm}^{-1}$ : 3430 (N-H stretch), 3285 (N-H stretch), 3054 (C-H stretch), 3019 (C-H stretch), 1627 (C=N stretch), 1587 (C=C stretch), 1548 (C=C stretch).

HRMS (ESI): Calc. for C<sub>15</sub>H<sub>15</sub>N<sub>2</sub><sup>+</sup>. Theoretical: 223.1230 Observed: 223.1225.

(Z)-N'-(cyclohex-1-en-1-yl)benzimidamide (**21**)



Chan-Lam procedure B (1.0 mmol scale boronic acid). Purification was carried out using a gradient 0% to 30% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording an off-white powder (83 mg, 41%).

Chan-Lam procedure C (1.00 mmol scale boronic acid). Purification was carried out using a gradient 0% to 30% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a white powder (66 mg, 33%).

mp 103-105 °C.


<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$ /ppm: 7.76 (d, 2H,  $J = 7.1$  Hz, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.37-7.44 (m, 3H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH × 2-CH), 5.14 (br s, 1H, N-C<sub>q</sub>=CH), 5.00 (br s, 2H, NH<sub>2</sub>), 2.10-2.13 (m, 4H, N-C<sub>q</sub>=CH-CH<sub>2</sub>, N-C<sub>q</sub>-CH<sub>2</sub>), 1.72-1.77 (m, 2H, N-C<sub>q</sub>-CH<sub>2</sub>-CH<sub>2</sub>), 1.60-1.65 (m, 2H, N-C<sub>q</sub>-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>).

<sup>13</sup>C{<sup>1</sup>H} NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$ /ppm: 153.2 (C<sub>q</sub>), 144.0 (C<sub>q</sub>), 135.7 (C<sub>q</sub>), 129.7 (C-H), 127.9 (2 × C-H), 126.1 (2 × C-H), 109.5 (C-H), 27.5 (CH<sub>2</sub>), 23.9 (CH<sub>2</sub>), 22.6 (CH<sub>2</sub>), 22.0 (CH<sub>2</sub>).

IR (neat):  $\nu_{\max}/\text{cm}^{-1}$ : 3458 (N-H stretch), 3292 (N-H stretch), 3025 (C-H stretch), 2928 (C-H alkyl stretch), 2909 (C-H alkyl stretch), 2850 (C-H alkyl stretch), 2831 (C-H alkyl stretch), 1651 (C=N stretch), 1574 (C=C stretch).

HRMS (ESI): Calc. for C<sub>13</sub>H<sub>17</sub>N<sub>2</sub><sup>+</sup>. Theoretical: 201.1386 Observed: 201.1381.

(Z)-4-chloro-N'-phenylbenzimidamide (**24**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 40% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording an off-white powder (56 mg, 61%).

Chan-Lam procedure C (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 40% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a white powder (63 mg, 69%).

**mp** 129-132 °C.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.78 (d, 2H, *J* = 7.6 Hz, N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.41 (m, 2H, Cl-C<sub>q</sub>-CH × 2), 7.34-7.37 (m, 2H, N-C<sub>q</sub>-CH-CH × 2), 7.06-7.09 (m, 1H, N-C<sub>q</sub>-CH-CH-CH), 6.96 (d, 2H, *J* = 7.4 Hz, N-C<sub>q</sub>-CH × 2), 4.80 (br s, 2H, NH<sub>2</sub>).

**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm: 154.3 (C<sub>q</sub>), 149.1 (C<sub>q</sub>), 136.8 (C<sub>q</sub>), 134.0 (C<sub>q</sub>), 129.6 (2 × C-H), 128.8 (2 × C-H), 128.3 (C-H), 123.4 (2 × C-H), 121.6 (2 × C-H).

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3456 (N-H stretch), 3304 (N-H stretch), 3067 (C-H stretch), 3026 (C-H stretch), 1621 (C=N stretch), 1591 (C=C stretch), 1582 (C=C stretch), 1558 (C=C stretch).

**HRMS (ESI):** C<sub>13</sub>H<sub>12</sub>ClN<sub>2</sub><sup>+</sup>. Theoretical: 231.0684 Observed: 231.0677.

(*Z*)-3-methoxy-*N'*-phenylbenzimidamide (**25**)



Using HCl salt of amidine following Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording an off-white powder (48 mg, 53%).

**mp** 104-107 °C.


**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 7.43 (br s, 1H, N=C<sub>q</sub>-C<sub>q</sub>-CH-CH), 7.32-7.37 (m, 4H, 4 × CH), 7.05-7.09 (m, 1H, N-C<sub>q</sub>-CH-CH-CH), 6.98-7.04 (m, 3H, 3 × CH), 5.06 (br s, 2H, NH<sub>2</sub>), 3.86 (s, 3H, O-CH<sub>3</sub>).

**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm: 159.3 (C<sub>q</sub>), 154.8 (C<sub>q</sub>), 148.2 (C<sub>q</sub>), 136.3 (C<sub>q</sub>), 129.1 (2 × C-H), 129.0 (C-H), 122.8 (2 × C-H), 121.3 (C-H), 118.5 (C-H), 116.6 (C-H), 111.6 (C-H), 55.0 (O-CH<sub>3</sub>).

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3465 (N-H stretch), 3335 (N-H stretch), 3056 (C-H stretch), 2922 (C-H alkyl stretch), 2850 (C-H alkyl stretch), 2829 (C-H alkyl stretch), 1621 (C=N stretch), 1600 (C=C stretch), 1589 (C=C stretch), 1574 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>14</sub>H<sub>15</sub>N<sub>2</sub>O<sup>+</sup>. Theoretical: 227.1179 Observed: 227.1226.

(*Z*)-2-fluoro-*N'*-phenylbenzimidamide (**26**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1% Et<sub>3</sub>N modifier, affording a colourless solid (45 mg, 52%).

**mp** 95-99 °C.

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 8.09 (br s, 1H, N=C<sub>q</sub>-C<sub>q</sub>-CH), 7.40-7.46 (m, 1H, F-C<sub>q</sub>-CH), 7.33-7.37 (m, 2H, N-C<sub>q</sub>-CH-CH × 2), 7.22-7.26 (m, 1H, F-C<sub>q</sub>-CH-CH), 7.09-7.14 (m, 1H, F-C<sub>q</sub>-CH-CH-CH), 7.05-7.08 (m, 1H, N-C<sub>q</sub>-CH-CH-CH), 6.98 (d, 2H, *J* = 7.4 Hz, N-C<sub>q</sub>-CH × 2), 5.16 (br s, 2H, NH<sub>2</sub>).


$^{13}\text{C}\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 160.1 (d,  $J = 248.1$  Hz, C-F) 151.4 ( $\text{C}_q$ ), 148.1 ( $\text{C}_q$ ), 131.6 (d,  $J = 9.1$  Hz, C-H), 130.6 (d,  $J = 1.3$  Hz, C-H), 129.1 ( $2 \times$  C-H), 124.1 (d,  $J = 3.4$  Hz, C-H), 122.7 ( $2 \times$  C-H), 122.2 (d,  $J = 10.1$  Hz,  $\text{C}_q$ ), 121.2 (C-H), 115.6 (d,  $J = 23.6$  Hz, C-H).

$^{19}\text{F}\{^1\text{H}\}$  NMR (470 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : -115.2.

**IR (neat):**  $\nu_{\text{max}}/\text{cm}^{-1}$ : 3428 (N-H stretch), 3277 (N-H stretch), 3028 (C-H stretch), 1632 (C=N stretch), 1619 (C=N stretch), 1606 (C=C stretch), 1589 (C=C stretch).

**HRMS (ESI):** Calc. for  $\text{C}_{13}\text{H}_{12}\text{FN}_2^+$ . Theoretical: 215.0979 Observed: 215.0970.

(Z)-3-bromo-*N'*-phenylbenzimidamide (**27**)



Chan-Lam procedure B using corresponding amidine HCl salt (1.00 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording an off-white powder (133 mg, 49 %).

**mp** 103-106 °C.


$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 8.03 (br s, 1H, Br- $\text{C}_q$ -CH- $\text{C}_q$ ), 7.73 (d, 1H,  $J = 7.2$  Hz, N= $\text{C}_q$ - $\text{C}_q$ -CH-CH), 7.56 (d, 1H,  $J = 7.9$  Hz, Br- $\text{C}_q$ -CH-CH), 7.34-7.37 (m, 2H, N- $\text{C}_q$ -CH-CH  $\times 2$ ), 7.27-7.30 (m, 1H, Br- $\text{C}_q$ -CH-CH), 7.06-7.09 (m, 1H, N- $\text{C}_q$ -CH-CH-CH), 6.96 (2H, d,  $J = 7.2$  Hz, N- $\text{C}_q$ -CH  $\times 2$ ), 4.88 (2H, br s,  $\text{NH}_2$ ).

$^{13}\text{C}\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 153.5 ( $\text{C}_q$ ), 149.2 ( $\text{C}_q$ ), 137.9 ( $\text{C}_q$ ), 133.5 (C-H), 130.2 (C-H), 130.0 (C-H), 129.6 ( $2 \times$  C-H), 125.4, 123.3 (C-H), 122.7 ( $\text{C}_q$ ), 121.5 ( $2 \times$  C-H).

**IR (neat):**  $\nu_{\text{max}}/\text{cm}^{-1}$ : 3434 (N-H stretch), 3276 (N-H stretch), 3110 (N-H stretch), 3056 (C-H stretch), 1634 (C=N stretch), 1604 (C=C stretch), 1586 (C=C stretch), 1558 (C=C stretch).

**HRMS (ESI):** Calc. for  $\text{C}_{13}\text{H}_{12}\text{BrN}_2^+$ . Theoretical: 275.0178 Observed: 275.0177.

(Z)-4-methyl-*N'*-phenylbenzimidamide (**28**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $\text{Et}_3\text{N}$  modifier, affording a colourless solid (26 mg, 31%).

**mp** 130-133 °C.

$^1\text{H}$  NMR (500 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 7.72 (d, 2H,  $J = 6.6$  Hz, N= $\text{C}_q$ - $\text{C}_q$ -CH  $\times 2$ ), 7.32-7.35 (m, 2H, N- $\text{C}_q$ -CH-CH  $\times 2$ ), 7.24 (m, 2H,  $\text{H}_3\text{C}$ - $\text{C}_q$ -CH  $\times 2$ ), 7.05-7.08 (m, 1H, N- $\text{C}_q$ -CH-CH-CH), 6.97-6.99 (d, 2H,  $J = 7.4$  Hz, N- $\text{C}_q$ -CH  $\times 2$ ), 5.01 (br s, 2H,  $\text{NH}_2$ ), 2.40 (s, 3H,  $\text{CH}_3$ ).


$^{13}\text{C}\{^1\text{H}\}$  NMR (125 MHz,  $\text{CDCl}_3$ ):  $\delta/\text{ppm}$ : 155.2 ( $\text{C}_q$ ), 148.2 ( $\text{C}_q$ ), 140.6 ( $\text{C}_q$ ), 131.8 ( $\text{C}_q$ ), 129.0 ( $2 \times$  C-H), 128.8 (C-H), 126.4 ( $2 \times$  C-H), 122.8 ( $2 \times$  C-H), 121.4 ( $2 \times$  C-H), 20.9 ( $\text{CH}_3$ ).

**IR (neat):**  $\nu_{\text{max}}/\text{cm}^{-1}$ : 3441 (N-H stretch), 3292 (N-H stretch), 3067 (C-H stretch), 3051 (C-H stretch),

2915 (C-H alkyl stretch), 1627 (C=N stretch), 1587 (C=C stretch), 1563 (C=C stretch), 1578 (C=C stretch).

**HRMS (ESI):** Calc. for  $C_{14}H_{15}N_2^+$ . Theoretical: 211.1230 Observed: 211.1224.

(Z)-3-cyano-*N'*-phenylbenzimidamide (**29**)



Chan-Lam procedure B (0.40 mmol scale boronic acid). Purification was carried out using a gradient 0% to 50% EtOAc in petroleum ether (40-60) with 1%  $Et_3N$  modifier, affording a white powder (10 mg, 11%).

**mp** 105-109 °C.


**$^1H$  NMR** (500 MHz,  $CDCl_3$ ):  $\delta$ /ppm: 8.19 (br s, 1H,  $N\equiv C-C_q-CH-C_q$ ), 8.10 (d, 1H,  $J = 7.6$  Hz,  $N=C_q-CH-CH$ ), 7.76 (m, 1H,  $N\equiv C-C_q-CH-CH$ ) 7.55-7.59 (m, 1H,  $NC-C_q-CH-CH$ ), 7.35-7.39 (m, 2H,  $N-C_q-CH-CH \times 2$ ), 7.09-7.12 (m, 1H,  $N-C_q-CH-CH-CH$ ), 6.98 (d, 2H,  $J = 7.4$  Hz,  $N-C_q-CH \times 2$ ), 4.98 (br s, 2H,  $NH_2$ ).

**$^{13}C\{^1H\}$  NMR** (125 MHz,  $CDCl_3$ ):  $\delta$ /ppm: 152.6 ( $C_q$ ), 148.0 ( $C_q$ ), 136.2 ( $C_q$ ), 133.5 ( $C-H$ ), 130.7 ( $C-H$ ), 130.3 ( $C-H$ ), 129.2 ( $2 \times C-H$ ), 129.0 ( $C-H$ ), 123.4 ( $2 \times C-H$ ), 121.0 ( $C-H$ ), 117.7 ( $C\equiv N$ ), 112.5 ( $C_q$ ).

**IR (neat):**  $\nu_{max}/cm^{-1}$ : 3426 (N-H stretch), 3253 (N-H stretch), 3051 (C-H stretch), 3028 (C-H stretch), 2227 ( $C\equiv N$  stretch), 1640 (C=N stretch), 1619 (C=N stretch), 1589 (C=C stretch), 1578 (C=C stretch).

**HRMS (ESI):** Calc. for  $C_{14}H_{12}N_3^+$ . Theoretical: 222.1026 Observed: 222.1020.

(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-*N'*-phenylbenzimidamide (**30**)



Using Chan-Lam procedure C (0.20 mmol scale boronic acid). Purification was carried out by semi-preparative RP-HPLC using method B, affording a white amorphous solid (31 mg, 24%).

**$^1H$  NMR** (500 MHz,  $CDCl_3$ ):  $\delta$ /ppm: 11.21 (br s, 1H,  $CF_3-CO_2H$ ), 9.65 (br s, 1H,  $CF_3-CO_2H$ ), 9.13 (br s, 2H,  $NH_2$ ), 8.84 (br s, 3H,  $3 \times NH$ ), 7.89 (d, 2H,  $J = 8.6$  Hz,  $C_q-N=C_q-C_q-CH \times 2$ ) 7.82 (d, 2H,  $J = 8.8$  Hz,  $HN=C_q-C_q-CH \times 2$ ) 7.56-7.60 (m, 2H,  $N-C_q-CH \times 2$ ), 7.45-7.49 (m, 3H,  $N-C_q-CH-CH \times 2-CH$ ) 7.21 (d, 2H,  $J = 8.6$  Hz,  $O-C_q-CH \times 2$ ), 7.17 (d, 2H,  $J = 8.8$  Hz,  $O-C_q-CH \times 2$ ), 4.12-4.17 (m, 4H,  $O-CH_2 \times 2$ ), 1.81-1.88 (m, 4H,  $O-CH_2-CH_2 \times 2$ ), 1.57-1.65 (m, 2H,  $O-CH_2-CH_2-CH_2$ ).


**$^{13}C\{^1H\}$  NMR** (125 MHz,  $CDCl_3$ ):  $\delta$ /ppm: 164.7 ( $C_q$ ), 163.1 ( $C_q$ ), 163.0 ( $C_q$ ), 162.3 ( $C_q$ ), 134.8 ( $C_q$ ), 130.8 ( $2 \times C-H$ ), 130.1 ( $2 \times C-H$ ), 129.9 ( $2 \times C-H$ ), 128.2 ( $C-H$ ), 125.4 ( $2 \times C-H$ ), 120.0 ( $C_q$ ), 119.4 ( $C_q$ ), 114.7 ( $4 \times C-H$ ), 68.1 ( $CH_2$ ), 68.0 ( $CH_2$ ), 28.2 ( $2 \times CH_2$ ), 22.0 ( $CH_2$ ).

**$^{19}F\{^1H\}$  NMR** (470 MHz,  $CDCl_3$ ):  $\delta$ /ppm: -73.5.

**IR (neat):**  $\nu_{max}/cm^{-1}$ : 3326 (N-H Stretch), 3105 ( $CO_2H$  stretch), 2947 ( $CO_2H$  stretch), 1667 (C=O stretch), 1610 (C=N stretch), 1495 (C=C stretch).

**HRMS (ESI):** Calc. for  $C_{25}H_{29}N_4O_2^+$ . Theoretical: 417.2285 Observed: 417.2272.

(Z)-N'-([1,1'-biphenyl]-4-yl)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)benzimidamide (**31**)



Using Chan-Lam procedure C (0.20 mmol scale boronic acid). Purification was carried out by semi-preparative RP-HPLC using method B, affording a white amorphous solid (29 mg, 20%).

**<sup>1</sup>H NMR** (500 MHz, CDCl<sub>3</sub>): δ/ppm: 11.27 (br s, 1H, CF<sub>3</sub>-CO<sub>2</sub>H), 9.70 (br s, 1H, CF<sub>3</sub>-CO<sub>2</sub>H), 9.13 (s, 2H, NH<sub>2</sub>), 8.95 (br s, 1H, NH), 8.86 (s, 2H, NH<sub>2</sub>), 7.87-7.92 (m, 4H, 4 × CH), 7.82 (d, 2H, *J* = 9.0 Hz, HN=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.74 (d, 2H, *J* = 7.4 Hz, C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.51-7.56 (m, 4H, 4 × CH), 7.42-7.44 (m, 1H, C<sub>q</sub>-C<sub>q</sub>-CH-CH-CH), 7.23 (d, 2H, *J* = 8.7 Hz, O-C<sub>q</sub>-CH × 2), 7.18 (d, 2H, *J* = 9.0 Hz, O-C<sub>q</sub>-CH × 2), 4.13-4.18 (m, 4H, O-CH<sub>2</sub> × 2), 1.82-1.89 (m, 4H, O-CH<sub>2</sub>-CH<sub>2</sub> × 2), 1.59-1.65 (m, 2H, O-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>).


**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, CDCl<sub>3</sub>): δ/ppm: 164.7 (C<sub>q</sub>), 163.1 (C<sub>q</sub>), 163.0 (C<sub>q</sub>), 162.4 (C<sub>q</sub>), 139.8 (C<sub>q</sub>), 139.0 (C<sub>q</sub>), 134.2 (C<sub>q</sub>), 130.9 (2 × C-H), 130.2 (2 × C-H), 129.1 (2 × C-H), 128.1 (2 × C-H), 127.9 (C-H), 126.7 (2 × C-H), 125.9 (2 × C-H), 120.0 (C<sub>q</sub>), 119.4 (C<sub>q</sub>), 114.8 (4 × C-H), 68.1 (CH<sub>2</sub>), 68.0 (CH<sub>2</sub>), 28.2 (2 × CH<sub>2</sub>), 22.1 (CH<sub>2</sub>).

**<sup>19</sup>F{<sup>1</sup>H} NMR** (470 MHz, CDCl<sub>3</sub>): δ/ppm: -73.5.

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3320 (N-H stretch), 3125 (CO<sub>2</sub>H stretch), 2945 (CO<sub>2</sub>H stretch), 1671 (C=O stretch), 1610 (C=N stretch), 1493 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>31</sub>H<sub>33</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup>. Theoretical: 493.2598 Observed: 493.2590.

(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(4-(trifluoromethyl)phenyl)benzimidamide (**32**)



Using Chan-Lam procedure C (0.20 mmol scale boronic acid). Purification was carried out by semi-preparative RP-HPLC using method B, affording a white amorphous solid (30 mg, 21%).

**<sup>1</sup>H NMR** (500 MHz DMSO-*d*<sub>6</sub>): δ/ppm: 11.43 (br s, 1H, CF<sub>3</sub>-CO<sub>2</sub>H), 9.82 (br s, 1H, CF<sub>3</sub>-CO<sub>2</sub>H), 9.12 (br s, 3H, 3 × NH), 8.81 (br s, 2H, NH<sub>2</sub>), 7.94 (d, 2H, *J* = 8.5 Hz, F<sub>3</sub>C-C<sub>q</sub>-CH-CH × 2), 7.89 (d, 2H, *J* = 8.7 Hz, C<sub>q</sub>-N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.81 (d, 2H, *J* = 8.9 Hz, HN=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.67 (d, 2H, *J* = 7.8 Hz, F<sub>3</sub>C-C<sub>q</sub>-CH × 2), 7.22 (d, 2H, *J* = 8.9 Hz, O-C<sub>q</sub>-CH × 2), 7.16 (d, 2H, *J* = 8.7 Hz, O-C<sub>q</sub>-CH × 2), 4.12-4.16 (m, 4H, O-CH<sub>2</sub> × 2), 1.81-1.87 (m, 4H, O-CH<sub>2</sub>-CH<sub>2</sub> × 2), 1.57-1.63 (m, 2H, O-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>).

**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, DMSO-*d*<sub>6</sub>): δ/ppm: 164.6 (C<sub>q</sub>), 163.3 (C<sub>q</sub>), 163.0 (C<sub>q</sub>), 162.7 (C<sub>q</sub>), 139.0 (C<sub>q</sub>), 131.1 (2 × CH), 130.2 (2 × CH), 128.0 (q, *J* = 31.2 Hz, C<sub>q</sub>), 127.1 (q, *J* = 3.5 Hz, 2 × CH), 126.1 (2 × CH), 123.9 (q, *J* = 272.1 Hz, CF<sub>3</sub>), 119.9 (C<sub>q</sub>), 119.4 (C<sub>q</sub>), 114.8 (4 × CH), 68.0 (CH<sub>2</sub>), 68.1 (CH<sub>2</sub>), 28.2 (2 × CH<sub>2</sub>), 22.0 (CH<sub>2</sub>).


**<sup>19</sup>F{<sup>1</sup>H} NMR** (470 MHz, DMSO-*d*<sub>6</sub>): δ/ppm: -60.9, -73.6.

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3328 (N-H stretch), 3105 (CO<sub>2</sub>H stretch), 2947 (CO<sub>2</sub>H stretch), 2874 (CO<sub>2</sub>H stretch), 1667 (C=O stretch), 1608 (C=N stretch), 1495 (C=C stretch).



**HRMS (ESI):** C<sub>26</sub>H<sub>28</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> Theoretical: 485.2159 Observed: 485.2149.

(Z)-4-(((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(4-(dimethylamino)phenyl)benzimidamide (33)



Using Chan-Lam procedure C (0.20 mmol scale boronic acid). Purification was carried out by semi-preparative RP-HPLC using method B, affording a pale green amorphous solid (27 mg, 20%).

**<sup>1</sup>H NMR** (500 MHz DMSO-*d*<sub>6</sub>): δ/ppm: 10.90 (br s, 1H, CF<sub>3</sub>-CO<sub>2</sub>H), 9.45 (br s, 1H, CF<sub>3</sub>-CO<sub>2</sub>H), 9.12 (br s, 2H, NH<sub>2</sub>), 8.78 (br s, 2H, NH<sub>2</sub>), 8.49 (br s, 1H, NH), 7.86 (d, 2H, *J* = 8.9 Hz, C<sub>q</sub>-N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.81 (d, 2H, *J* = 8.9 Hz, HN=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.23 (d, 2H, *J* = 9.0 Hz, N-C<sub>q</sub>-CH × 2), 7.16-7.24 (m, 4H, O-C<sub>q</sub>-CH × 4), 6.85 (d, 2H, *J* = 8.7 Hz, (H<sub>3</sub>C)<sub>2</sub>N-C<sub>q</sub>-CH × 2), 4.12-4.16 (m, 4H, O-CH<sub>2</sub> × 2), 2.97 (s, 6H, N(CH<sub>3</sub>)<sub>2</sub>), 1.81-1.87 (m, 4H, O-CH<sub>2</sub>-CH<sub>2</sub> × 2), 1.59-1.64 (m, 2H, O-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>).


**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, DMSO-*d*<sub>6</sub>): δ/ppm: 164.5 (C<sub>q</sub>), 163.1 (C<sub>q</sub>), 162.9 (C<sub>q</sub>), 162.3 (C<sub>q</sub>), 150.0 (C<sub>q</sub>), 130.5 (2 × CH), 130.2 (2 × CH), 126.6 (2 × CH), 122.7 (C<sub>q</sub>), 120.1 (C<sub>q</sub>), 119.4 (C<sub>q</sub>), 114.8 (2 × CH), 114.7 (2 × CH), 112.8 (2 × CH), 68.0 (CH<sub>2</sub>), 68.1 (CH<sub>2</sub>), 39.70 (N(CH<sub>3</sub>)<sub>2</sub>), Observed from a HSQC experiment), 28.2 (2 × CH<sub>2</sub>), 22.1 (CH<sub>2</sub>).

**<sup>19</sup>F{<sup>1</sup>H} NMR** (470 MHz, DMSO-*d*<sub>6</sub>): δ/ppm: -73.7.

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3327 (N-H stretch), 3105 (CO<sub>2</sub>H stretch), 2947 (CO<sub>2</sub>H stretch), 2874 (CO<sub>2</sub>H stretch), 1647 (C=O stretch), 1608 (C=N stretch), 1592 (C=C stretch), 1490 (C=C stretch).

**HRMS (ESI):** Calc. for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup>. Theoretical: 460.2707 Observed: 460.2712.

(Z)-4-(((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(3-fluoro-4-methoxyphenyl)benzimidamide (34)



Using Chan-Lam procedure C (0.20 mmol scale boronic acid). Purification was carried out by semi-preparative RP-HPLC using method B, affording a white amorphous solid (28 mg, 20%).

**<sup>1</sup>H NMR** (500 MHz, DMSO-*d*<sub>6</sub>): δ/ppm: 11.14, (br s, 1H, CF<sub>3</sub>-CO<sub>2</sub>H), 9.62 (br s, 1H, CF<sub>3</sub>-CO<sub>2</sub>H) 9.13 (br s, 2H, NH<sub>2</sub>), 8.90 (br s, 2H, NH<sub>2</sub>), 8.75 (br s, 1H, NH), 7.87 (d, 2H, *J* = 8.7 Hz, C<sub>q</sub>-N=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.82 (d, 2H, *J* = 8.9 Hz, HN=C<sub>q</sub>-C<sub>q</sub>-CH × 2), 7.45 (d, 1H, *J* = 10.7 Hz, N-C<sub>q</sub>-CH-CF), 7.33-7.38 (m, 1H, N-C<sub>q</sub>-CH-CH), 7.16-7.26 (m, 5H, 5 × CH), 4.12-4.16 (m, 4H, O-CH<sub>2</sub> × 2), 3.91 (s, 3H, CH<sub>3</sub>), 1.83-1.86 (m, 4H, O-CH<sub>2</sub>-CH<sub>2</sub> × 2), 1.57-1.65 (m, 2H, O-CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>).


**<sup>13</sup>C{<sup>1</sup>H} NMR** (125 MHz, DMSO-*d*<sub>6</sub>): δ/ppm: 165.2 (C<sub>q</sub>), 163.6 (C<sub>q</sub>), 163.5 (C<sub>q</sub>), 163.3 (C<sub>q</sub>), 151.9 (d, *J* = 248.9 Hz, C-F), 147.6 (C<sub>q</sub>), 131.2 (2 × C-H), 130.6 (2 × C-H), 127.6 (C<sub>q</sub>), 123.2 (C-H), 120.4 (C<sub>q</sub>), 119.9 (C<sub>q</sub>), 115.3 (2 × C-H), 115.2 (2 × C-H), 115.0 (C-H) 114.8 (d, *J* = 20.0 Hz, C-H), 68.6 (CH<sub>2</sub>), 68.5 (CH<sub>2</sub>), 56.8 (CH<sub>3</sub>), 28.7 (CH<sub>2</sub>), 22.6 (CH<sub>2</sub>).

**<sup>19</sup>F{<sup>1</sup>H} NMR** (470 MHz, DMSO-*d*<sub>6</sub>): δ/ppm: -73.7, -132.5.

**IR (neat):** ν<sub>max</sub>/cm<sup>-1</sup>: 3330 (N-H stretch), 3095 (CO<sub>2</sub>H stretch), 2943 (CO<sub>2</sub>H stretch), 2874 (CO<sub>2</sub>H stretch), 1669 (C=O stretch), 1610 (C=N stretch), 1521 (C=C stretch), 1495 (C=C stretch).

**HRMS (ESI):** Calc. for  $C_{26}H_{30}FN_4O_3^+$ . Theoretical: 465.2296 Observed: 465.2289.

(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(quinolin-3-yl)benzimidamide (**35**)



Using Chan-Lam procedure C (0.20 mmol scale boronic acid). Purification was carried out by semi-preparative RP-HPLC using method B, affording a white amorphous solid (21 mg, 15%).


**$^1H$  NMR** (500 MHz,  $CDCl_3$ ):  $\delta$ /ppm: 11.6 (br s, 1H,  $CF_3-CO_2H$ ), 9.83 (br s, 1H,  $CF_3-CO_2H$ ), 9.14 (br s, 3H, 3  $\times$  NH), 8.98 (br s, 1H, N- $C_q-CH-N$ ), 8.93 (br s, 2H,  $NH_2$ ), 8.52 (br s, 1H, N- $C_q-CH-C_q$ ), 8.09-8.14 (m, 2H, N- $C_q-CH-C_q-CH-CH$ ), 7.97 (d, 2H,  $J = 8.5$  Hz,  $C_q-N=C_q-C_q-CH \times 2$ ), 7.86-7.90 (m, 1H, N- $C_q-CH-N-C_q-CH$ ), 7.83 (d, 2H,  $J = 8.9$  Hz,  $HN=C_q-C_q-CH \times 2$ ), 7.71-7.74 (m, 1H, N- $C_q-CH-N-C_q-CH-CH$ ), 7.25 (d, 2H,  $J = 8.5$  Hz, O- $C_q-CH \times 2$ ), 7.17 (d, 2H,  $J = 8.9$  Hz, O- $C_q-CH \times 2$ ), 4.13-4.19 (m, 4H, O- $CH_2 \times 2$ ), 1.82-1.90 (m, 4H, O- $CH_2-CH_2 \times 2$ ), 1.58-1.66 (m, 2H, O- $CH_2-CH_2-CH_2$ ).

**$^{13}C\{^1H\}$  NMR** (125 MHz,  $CDCl_3$ ):  $\delta$ /ppm: 164.6 ( $C_q$ ), 163.4 ( $C_q$ ), 163.3 ( $C_q$ ), 163.0 ( $C_q$ ), 158.1 ( $C_q$ ), 157.8 ( $C_q$ ), 148.2 (C-H), 146.6 ( $C_q$ ), 132.5 (C-H), 130.9 (2  $\times$  C-H), 130.4 (C-H), 130.2 (2  $\times$  C-H), 128.8 (C-H), 128.4 (C-H), 127.6 (C-H), 119.8 ( $C_q$ ), 119.4 ( $C_q$ ), 114.8 (2  $\times$  C-H), 114.7 (2  $\times$  C-H), 68.1 ( $CH_2$ ), 68.0 ( $CH_2$ ), 28.2 (2  $\times$   $CH_2$ ), 22.1 ( $CH_2$ ).

**$^{19}F\{^1H\}$  NMR** (470 MHz,  $CDCl_3$ ):  $\delta$ /ppm: -73.7.

**IR (neat):**  $\nu_{max}/cm^{-1}$ : 3326 (N-H stretch), 3093 ( $CO_2H$  stretch), 2943 ( $CO_2H$  stretch), 1667 (C=O stretch), 1608 (C=N stretch), 1493 (C=C stretch).

(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(3-((5-(dimethylamino)naphthalene)-1-sulfonamido)phenyl)benzimidamide (**36**)



Using Chan-Lam procedure C (0.20 mmol scale boronic acid). Purification was carried out by semi-preparative RP-HPLC using method B, affording a white amorphous solid (6 mg, 5%).

**$^1H$  NMR** (500 MHz,  $DMSO-d_6$ ):  $\delta$  11.12 (br s, 1H,  $CF_3-CO_2H$ ), 11.05 (br s, 1H, NH) 9.63 (br s, 1H,  $CF_3-CO_2H$ ), 9.13 (s, 2H,  $NH_2$ ), 8.90 (s, 2H,  $NH_2$ ), 8.82 (br s, 1H, NH), 8.84 (d, 1H,  $J = 8.4$  Hz,  $HN-SO_2-C_q-C_q-CH$ ), 8.38 (d, 1H,  $J = 8.7$  Hz,  $HN-SO_2-C_q-C_q-CH$ ), 8.28 (d, 1H,  $J = 7.2$  Hz,  $HN-SO_2-C_q-CH$ ), 7.82 (d, 4H,  $J = 8.9$  Hz, 4  $\times$  CH) 7.62-7.66 (m, 2H, 2  $\times$  CH), 7.33-7.37 (m, 1H, C=N- $C_q-CH-CH$ ), 7.27 (d, 1H,  $(CH_3)_2N-C_q-CH$ ), 7.15-7.18 (m, 4H, 4  $\times$  CH), 7.09-7.11 (m, 2H, 2  $\times$  CH), 7.02 (d, 1H,  $J = 6.2$  Hz, C=N- $C_q-CH-CH$ ), 4.12-4.15 (m, 4H, O- $CH_2 \times 2$ ), 2.82 (s, 6H, N( $CH_3$ )<sub>2</sub>), 1.80-1.86 (m, 4H, O- $CH_2-CH_2 \times 2$ ), 1.57-1.62 (m, 2H, O- $CH_2-CH_2-CH_2$ ).


**$^{13}C\{^1H\}$  NMR** (125 MHz,  $DMSO-d_6$ ):  $\delta$  164.6 ( $C_q$ ), 163.1 ( $C_q$ ), 163.0 ( $C_q$ ), 158.2 ( $C_q$ ), 157.9 ( $C_q$ ), 151.5 ( $C_q$ ), 139.3 ( $C_q$ ), 135.6 ( $C_q$ ), 134.7 ( $C_q$ ), 130.9 (2  $\times$  C-H), 130.7 ( $C_q$ ), 130.3 (C-H), 130.2 (2  $\times$  C-H), 129.7 (C-H), 129.0 (C-H), 128.9 ( $C_q$ ), 123.5 (C-H), 119.8 ( $C_q$ ), 119.6 (C-H), 118.5 (C-H), 117.2 (C-H), 115.3 (C-H), 114.7 (2  $\times$  C-H), 114.6 (2  $\times$  C-H), 68.1 ( $CH_2$ ), 68.0 ( $CH_2$ ), 45.0 (2  $\times$   $CH_3$ ) 28.2 (2  $\times$   $CH_2$ ), 22.0 ( $CH_2$ ).

$^{19}\text{F}\{^1\text{H}\}$  NMR (470 MHz, DMSO-*d*6):  $\delta$  -73.9.

$\nu_{\text{max}}$  (neat): 3100 (CO<sub>2</sub>H stretch), 3087 (CO<sub>2</sub>H stretch), 1657 (C=O stretch), 1608 (C=N stretch), 1485 (C=C stretch).

HRMS (ESI): Calc. for C<sub>37</sub>H<sub>41</sub>N<sub>6</sub>O<sub>4</sub>S<sup>+</sup>. Theoretical: 665.2905 Observed: 665.2896.

#### Complex 4



To an oven dried 100 mL round-bottomed flask was added was added benzamidine **1** (1.00 g, 8.32 mmol), Cu(OAc)<sub>2</sub> (785 mg, 4.32 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.15 g, 8.32 mmol). Isopropanol (18.1 mL) was then added to the solid mixture, sealed under air, and stirred at room temperature for 2 h. The resulting purple suspension was filtered, and the purple precipitate was dried under high vacuum to yield a purple powder-like solid (2.01 g). This purple powder was then recrystallised from MeCN and subjected to a hot filtration to afford deep purple crystals (80 mg, 5%). Crystallographic data in tables S8 – S13.

### Trypanosoma experiments

#### Resazurin-based drug sensitivity assay

The synthesised pentamidine analogues were tested for anti-kinetoplastid activity using the resazurin ('alamar blue') assay as described previously.<sup>2</sup> The bloodstream forms (BSF) of *Trypanosoma brucei brucei* s427WT and the multidrug resistant strain B48 were cultured and maintained in HMI-9 medium supplemented with 10% heat inactivated Fetal Bovine Serum (FBS), 14  $\mu\text{L/L}$   $\beta$ -mercaptoethanol, and 3.0 g/L NaHCO<sub>3</sub> adjusted to pH 7.4, and incubated at 37 °C in a 5% CO<sub>2</sub> atmosphere. BSF *T. congolense* Tc-IL3000 WT and diminazene-resistant *T. congolense* strain 6C3 were cultured as described previously<sup>3,4</sup>, at 34 °C/5% CO<sub>2</sub> in basal medium prepared with MEM medium (Sigma-Aldrich), 26 mM NaHCO<sub>3</sub>, 25 mM HEPES, 5.6 mM D-glucose, 1 mM sodium pyruvate, 100  $\mu\text{M}$  hypoxanthine, 40  $\mu\text{M}$  adenosine, 16.5  $\mu\text{M}$  thymidine, and 25  $\mu\text{M}$  bathocuproine disulfonic acid disodium salt, supplemented with 1.6 mM glutamine, 100 units/mL penicillin, 0.1 mg/mL streptomycin,  $\beta$ -mercaptoethanol (0.0014% v/v), 15% goat serum (Gibco), and 5% Serum Plus II (Sigma Aldrich). The promastigote stage of *Leishmania mexicana* WT (strain MNY/BZ/62/M379) used in this study was cultured at 27 °C in custom-made HOMEM medium (Gibco) supplemented with 10% FBS as described.<sup>5</sup>

Briefly, 200  $\mu\text{L}$  of 40  $\mu\text{M}$  of each test compound in the appropriate medium was placed in the first well of a row of a 96-well plate (Greiner Bio-one GmbH, Frickenhausen, Germany). 100  $\mu\text{L}$  of fresh media was added to the 11 other wells in the row and a double serial dilution was performed while leaving the 12<sup>th</sup> well as drug-free. Pentamidine and diminazene were used as positive control.


The cells were then adjusted to a density of  $2 \times 10^5$ ,  $5 \times 10^5$  or  $2 \times 10^6$  cells/ml in the appropriate medium for *T. brucei*, *T. congolense* and *L. mexicana* respectively and of these cell suspensions 100  $\mu$ L was added to the appropriate wells. This was followed by incubation for 48 h for the *Trypanosoma* spp or 72 h for *Leishmania*, after which 20  $\mu$ L of 125  $\mu$ g/mL resazurin sodium salt (Sigma) in PBS was added. The assay is based on the ability of live cells to reduce blue, non-fluorescent resazurin to pink, fluorescent resorufin - a reaction that does not occur with dead cells - producing a fluorescent signal proportionate to cell numbers (Gould et al., 2008). The plates were further incubated for 24 h for the trypanosomes or 48 h for *Leishmania* under the same conditions. Fluorescence was then determined using a FLUOstar Optima (BMG Labtech, Durham, NC, USA) at  $\lambda_{exc} = 544$  nm and  $\lambda_{em} = 590$  nm, and a half maximal effective concentration ( $EC_{50}$ ) was calculated for each compound by non-linear regression using an equation for a sigmoidal dose-response curve with variable slope (GraphPad Prism 5.0, GraphPad Software Inc., San Diego).

#### *Real-time measurement of fluorescence in parasites*

The uptake of compound **36** was measured in real time using a fluorimeter, essentially as described previously but with some modifications.<sup>6</sup> Cultures of *T. b. brucei*, *T. congolense* and *L. mexicana* were harvested at mid-log growth phase by centrifugation for 10 min at 2400 rpm. The cells were washed twice in assay buffer and resuspended at a density of  $10^8$  cells/mL; 100  $\mu$ L/well of each cell suspension was transferred to wells of a white opaque 96-well culture plate. Different dilutions of **36** were prepared at twice the desired final concentration in assay buffer with or without pentamidine, and 100  $\mu$ L of the drug preparation was then transferred to designated wells containing cells of the plate. The plate was inserted into a microplate reader (FLUOstar Optima, BMG Labtech) set at 37 °C and 5% CO<sub>2</sub>, and fluorescence was measured over time using 355/520 excitation and emission filters.

#### *Localisation of cellular targets using fluorescence microscopy*

Fluorescence microscopy was carried out to locate the target of **36** using DNA and mitochondrial markers as described previously (Cueto-Díaz et al., 2021). Briefly, about  $2 \times 10^6$  *T. b. brucei* cells were incubated with 10  $\mu$ M **36** in complete HMI-9 for 30 min, followed by the addition of MitoTracker Green FM (Invitrogen, M7514) to a final concentration of 100 nM and a by further incubation for 10 min (at 37°C and 5% CO<sub>2</sub>). The cells were then centrifuged at 2400 rpm for 10 min, and the pellet was washed once and resuspended in sterile 1 $\times$  PBS, pH 7.4. Hoechst 33342 Staining Dye Solution (Abcam, ab228551) was then added to the sample at 5  $\mu$ g/mL followed by incubation in the dark at room temperature for 10 min. The cells were washed again in ice-cold, sterile 1 $\times$  PBS by centrifugation and the pellet re-suspended in 50  $\mu$ L of ice-chilled PBS-primed CyGEL™ (Abcam, ab109204) for immobilisation. The sample was then transferred into a clean glass slide on ice, covered with coverslip and sealed with nail varnish. Images were acquired immediately, using a DeltaVision microscope (GE Healthcare) and softWoRx software, and processed with the ImageJ software package.




**Figure S4.** Fluorescence microscopy images of trypanosoma using pentamidine analogue **36**.

#### *DNA UV Melt Analysis*

DNA UV melt analyses were performed on a Shimadzu 1800 UV/Vis spectrometer equipped with a peltier temperature controller using a 1 cm pathlength cell. ON1/ON1c (5' GGA AAT TTG C 3')/(5' GCA AAT TTC C 3') and ON2/ON2c (5' GGA TAT ATG C 3')/(5' GCA TAT ATC C 3') were purchased from Eurogentec. ON pairs were analysed using a buffer containing 10 mM monobasic phosphate, 10 mM dibasic phosphate and 100 mM NaCl corrected to pH 7.0. Pentamidine analogues were dissolved in DMSO and added to give a DMSO content <0.1%. The final duplex ON concentration was 2  $\mu$ M and each DNA ligand was added to an 8  $\mu$ M (4 eq.) concentration. Denaturing profiles were recorded from 20  $^{\circ}$ C to 90  $^{\circ}$ C at a rate of 1  $^{\circ}$ C/min with three concordant melt profiles produced. Each ON pair was independently repeated 3 times. The reported melting temperatures were produced from a gaussian fit of the 1<sup>st</sup> derivative of the melt profile and averaged across the technical and biological repeats (n=9). Significance values were calculated using Student unpaired two-tailed t-test (\*\*\*\* P  $\leq$  0.0001).

**Table S7.** Calculated melt temperatures ( $T_m$ ) and change in melt temperatures ( $\Delta T_m$ ).


	$T_m$ ( $^{\circ}$ C)				
	Free ON	PMD	33	36	DA
ON1/ON1c	38.29 $\pm$ 0.21	44.23 $\pm$ 0.16	45.19 $\pm$ 0.20	42.86 $\pm$ 0.45	51.16 $\pm$ 0.12
ON2/ON2c	32.49 $\pm$ 0.11	37.36 $\pm$ 0.12	37.97 $\pm$ 0.10	35.63 $\pm$ 0.61	44.22 $\pm$ 0.15
	$\Delta T_m$ ( $^{\circ}$ C)				
ON1/ON1c		5.94 $\pm$ 0.26	6.89 $\pm$ 0.29	4.56 $\pm$ 0.50	12.90 $\pm$ 0.24
ON2/ON2c		4.86 $\pm$ 0.16	5.48 $\pm$ 0.15	3.14 $\pm$ 0.62	11.70 $\pm$ 0.19




**Figure S4.** Comparison of the DNA duplex stabilisation ( $\Delta T_m$ ) for a range of minor groove binding ligands. PMD, pentamidine; DA, diminazene aceturate, **33** and **36**. Significance values were calculated using Student unpaired two-tailed t-test (\*\*\*\*  $P \leq 0.0001$ ).

# NMR spectra


(Z)-N'-phenylbenzimidamide (2) - <sup>1</sup>H NMR



(Z)-N,N'-diphenylbenzimidamide (**3**) - <sup>1</sup>H NMR




<sup>13</sup>C NMR





(Z)-N'-(4-fluorophenyl)benzimidamide (7) - <sup>1</sup>H NMR




Current Data Parameters  
NAME JR0237B-E38730  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190106  
Time 19.01 h  
INSTRUM spect  
PROBHD Z113652\_0211 ( )  
PULPROG zg30  
TD 39578  
SOLVENT CDCl3  
NS 16  
DS 2  
SWH 10000.000 Hz  
FIDRES 0.505331 Hz  
AQ 1.9789000 sec  
RG 198.22  
DW 50.000 usec  
DE 6.50 usec  
TE 300.0 K  
D1 2.00000000 sec  
TDO 1  
SFO1 500.1330885 MHz  
NUC1 1H  
P1 10.00 usec  
PLW1 20.00000000 W

F2 - Processing parameters  
SI 65536  
SF 500.1300143 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

<sup>13</sup>C NMR



Current Data Parameters  
NAME JR0237 Carbon-D311600  
EXPNO 1  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20190113  
Time 6.48  
INSTRUM spect  
PROBHD 5 mm CPBBO BB  
PULPROG zgpg30  
TD 16384  
SOLVENT CDCl3  
NS 8192  
DS 4  
SWH 25252.525 Hz  
FIDRES 1.541292 Hz  
AQ 0.3244032 sec  
RG 2050  
DW 19.800 usec  
DE 18.00 usec  
TE 300.0 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TDO 1

----- CHANNEL f1 -----  
SFO1 100.6228298 MHz  
NUC1 13C  
P1 10.00 usec  
PLW1 35.00000000 W


----- CHANNEL f2 -----  
SFO2 400.1316005 MHz  
NUC2 1H  
CPDPRG[2] waltz16  
PCPD2 90.00 usec  
PLW2 7.50000000 W  
PLW12 0.16379000 W  
PLW13 0.08238400 W

F2 - Processing parameters  
SI 32768  
SF 100.6128193 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40


<sup>19</sup>F NMR



(Z)-N'-4-(methylthio)phenylbenzimidamide (8) - <sup>1</sup>H NMR



<sup>13</sup>C NMR




Current Data Parameters  
 NAME JR0278-E40878  
 EXPNO 2  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20190330  
 Time 2.28 h  
 INSTRUM spect  
 PROBHD Z113652\_0211 {  
 PULPROG zgpg30  
 TD 23806  
 SOLVENT CDCl3  
 NS 8192  
 DS 4  
 SWH 29761.90 Hz  
 FIDRES 2.500370 Hz  
 AQ 0.3999408 sec  
 RG 198.22  
 DM 16.800 usec  
 DE 6.50 usec  
 TE 299.9 K  
 D1 2.00000000 sec  
 D11 0.03000000 sec  
 TDO 1  
 SFO1 125.7703637 MHz  
 NUC1 13C  
 P0 3.33 usec  
 P1 10.00 usec  
 PLW1 76.0000000 W  
 SFO2 500.1320005 MHz  
 NUC2 1H  
 CPDPRG2 waltz16  
 PCPD2 80.00 usec  
 PLW2 21.00000000 W  
 PLW12 0.31513000 W  
 PLW13 0.15851000 W

F2 - Processing parameters  
 SI 32768  
 SF 125.7577885 MHz  
 WDN EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40

(Z)-N'-(4-(tert-butyl)phenyl)benzimidamide (9) - <sup>1</sup>H NMR




Current Data Parameters  
 NAME JR0236B-E38719  
 EXPNO 1  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20190104  
 Time 15.12 h  
 INSTRUM spect  
 PROBHD Z113652\_0211 {  
 PULPROG zg30  
 TD 39578  
 SOLVENT CDCl3  
 NS 16  
 DS 2  
 SWH 10000.000 Hz  
 FIDRES 0.505331 Hz  
 AQ 1.9789000 sec  
 RG 198.22  
 DW 50.000 usec  
 DE 6.50 usec  
 TE 300.0 K  
 D1 2.00000000 sec  
 TDO 1  
 SFO1 500.1330885 MHz  
 NUC1 1H  
 P1 10.00 usec  
 PLW1 20.00000000 W

F2 - Processing parameters  
 SI 65536  
 SF 500.1300132 MHz  
 WDN EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00


<sup>13</sup>C NMR



(Z)-N'-(4-(trifluoromethyl)phenyl)benzimidamide (10) - <sup>1</sup>H NMR



<sup>13</sup>C NMR




Current Data Parameters  
NAME JR0242 Fluorine and carbon -D316978  
EXPNO 2  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190414  
Time 3.17 h  
INSTRUM spect  
PROBHD E122623\_0021 (  
PULPROG zgpg30  
TD 16384  
SOLVENT CDCl3  
NS 8192  
DS 4  
SWH 25252.525 Hz  
FIDRES 3.082584 Hz  
AQ 0.3244032 sec  
RG 2050  
DW 19.800 usec  
DE 18.00 usec  
TE 300.0 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TDO 1  
SF01 100.6228298 MHz  
NUC1 13C  
P0 3.33 usec  
P1 10.00 usec  
PLM1 35.0000000 W  
SF02 400.1316005 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLM2 7.5000000 W  
PLM12 0.16379000 W  
PLM13 0.08238400 W

F2 - Processing parameters  
SI 32768  
SF 100.6128193 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

<sup>19</sup>F NMR




Current Data Parameters  
NAME JR0242 Fluorine and carbon -D316978  
EXPNO 1  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20190413  
Time 14.31 h  
INSTRUM spect  
PROBHD E122623\_0021 (  
PULPROG zg30  
TD 261896  
SOLVENT CDCl3  
NS 32  
DS 4  
SWH 89285.711 Hz  
FIDRES 0.661841 Hz  
AQ 1.4666176 sec  
RG 25.4  
DW 5.600 usec  
DE 18.37 usec  
TE 300.0 K  
D1 2.0000000 sec  
TDO 1  
SF01 376.4607162 MHz  
NUC1 19F  
P0 5.00 usec  
P1 15.00 usec  
PLM1 5.19999981 W

F2 - Processing parameters  
SI 262144  
SF 376.4983660 MHz  
WDW EM  
SSB 0  
LB 0.50 Hz  
GB 0  
PC 1.00


(Z)-N'-(m-tolyl)benzimidamide (11) - <sup>1</sup>H NMR




<sup>13</sup>C NMR




(Z)-N'-([1,1'-biphenyl]-4-yl)benzimidamide (12) - <sup>1</sup>H NMR



<sup>13</sup>C NMR



(Z)-N'-(o-tolyl)benzimidamide (**13**) - <sup>1</sup>H NMR




Current Data Parameters  
 NAME JR0234B-E38728  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20190106  
 Time 14.14 h  
 INSTRUM spect  
 PROBHD Z113652\_0211 ( )  
 PULPROG zg30  
 TD 39578  
 SOLVENT CDCl3  
 NS 16  
 DS 2  
 SWH 10000.000 Hz  
 FIDRES 0.505331 Hz  
 AQ 1.9789000 sec  
 RG 198.22  
 DW 50.000 usec  
 DE 6.50 usec  
 TE 300.0 K  
 D1 2.00000000 sec  
 TDD 1  
 SFO1 500.1330885 MHz  
 NUC1 1H  
 P1 10.00 usec  
 PLW1 20.00000000 W

F2 - Processing parameters  
 SI 65536  
 SF 500.1300145 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

<sup>13</sup>C NMR



Current Data Parameters  
 NAME JR0234 Carbon-0311551  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20190112  
 Time 6.18  
 INSTRUM spect  
 PROBHD 5 mm CFPBBO BB  
 PULPROG zgpg30  
 TD 16384  
 SOLVENT CDCl3  
 NS 8192  
 DS 4  
 SWH 25252.525 Hz  
 FIDRES 1.541292 Hz  
 AQ 0.3244032 sec  
 RG 2050  
 DW 19.800 usec  
 DE 18.00 usec  
 TE 300.0 K  
 D1 2.00000000 sec  
 D11 0.03000000 sec  
 TDD 1


----- CHANNEL f1 -----  
 SFO1 100.6228298 MHz  
 NUC1 13C  
 P1 10.00 usec  
 PLW1 35.00000000 W

----- CHANNEL f2 -----  
 SFO2 400.1316005 MHz  
 NUC2 1H  
 CPDPRG2 waltz16  
 FREQ2 90.00 usec  
 PLM2 7.50000000 W  
 PLM12 0.16379000 W  
 PLM13 0.08238400 W


F2 - Processing parameters  
 SI 32768  
 SF 100.6128661 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40




(Z)-N'-(2-methoxyphenyl)benzimidamide (14) - <sup>1</sup>H NMR




<sup>13</sup>C NMR




(Z)-N<sup>1</sup>-(pyridin-3-yl)benzimidamide trifluoroacetate (**15**) - <sup>1</sup>H NMR



<sup>13</sup>C NMR



<sup>19</sup>F NMR




— -73.39




Current Data Parameters  
NAME JR0241 Fluorine-E43449  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190816  
Time 11.30 h  
INSTRUM spect  
PROBHD zll13652\_0211 (  
PULPROG zgfhigqn.2  
TD 131072  
SOLVENT DMSO  
NS 16  
DS 4  
SWH 113636.367 Hz  
FIDRES 1.733953 Hz  
AQ 0.5767168 sec  
RG 198.22  
DW 4.400 usec  
DE 6.50 usec  
TE 300.0 K  
D1 1.00000000 sec  
D11 0.03000000 sec  
D12 0.00002000 sec  
TD0 1  
SFO1 470.5453180 MHz  
NUC1 19F  
P1 15.00 usec  
PLW1 35.00000000 W  
SFO2 500.1320005 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 80.00 usec  
PLM2 21.00000000 W  
PLM12 0.31313000 W

F2 - Processing parameters  
SI 131072  
SF 470.5923772 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00




(Z)-N'-(3-fluoro-4-methoxyphenyl)benzimidamide (16) - <sup>1</sup>H NMR





Current Data Parameters  
NAME JR0244B-E38720  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190104  
Time 15.20 h  
INSTRUM spect  
PROBHD zll13652\_0211 (  
PULPROG zg30  
TD 39578  
SOLVENT CDC13  
NS 16  
DS 2  
SWH 10000.000 Hz  
FIDRES 0.505331 Hz  
AQ 1.9789000 sec  
RG 198.22  
DW 50.000 usec  
DE 6.50 usec  
TE 300.0 K  
D1 2.00000000 sec  
TD0 1  
SFO1 500.1330885 MHz  
NUC1 1H  
P1 10.00 usec  
PLW1 20.00000000 W

F2 - Processing parameters  
SI 65536  
SF 500.1300133 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00



# <sup>13</sup>C NMR





Current Data Parameters  
NAME JRO244-Fluorine and Carbon E41184  
EXPNO 2  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190414  
Time 1.12 h  
INSTRUM spect  
PROBHD Z113652\_0211 ( )  
PULPROG zgpg30  
TD 23896  
SOLVENT CDCl3  
NS 4  
DS 4  
SWH 29761.904 Hz  
FIDRES 2.550370 Hz  
AQ 0.3389408 sec  
RG 198.22  
DW 16.800 usec  
DE 6.50 usec  
TE 300.0 K  
D1 1.0000000 sec  
D11 0.0300000 sec  
TDO 1  
SFO1 125.7703637 MHz  
NUC1 13C  
P0 3.33 usec  
F1 10.00 usec  
PLM1 76.0000000 W  
SFO2 500.1320005 MHz  
NUC2 1H  
CFDPRG2 waltz16  
PCPD2 80.00 usec  
PLM2 21.0000000 W  
PLM12 0.31513000 W  
PLM13 0.15851000 W

F2 - Processing parameters  
SI 32768  
SF 125.7577885 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

# <sup>19</sup>F NMR




Current Data Parameters  
NAME JRO244 Fluorine-E43450  
EXPNO 1  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20190816  
Time 11.38 h  
INSTRUM spect  
PROBHD Z113652\_0211 ( )  
PULPROG zgfhgqg.2  
TD 131072  
SOLVENT CDCl3  
NS 16  
DS 4  
SWH 113636.367 Hz  
FIDRES 1.733953 Hz  
AQ 0.5767168 sec  
RG 198.22  
DW 4.400 usec  
DE 6.50 usec  
TE 300.0 K  
D1 1.0000000 sec  
D11 0.0300000 sec  
D12 0.00002000 sec  
TDO 1  
SFO1 470.5453180 MHz  
NUC1 19F  
P1 15.00 usec  
PLM1 35.0000000 W  
SFO2 500.1320005 MHz  
NUC2 1H  
CFDPRG2 waltz16  
PCPD2 80.00 usec  
PLM2 21.0000000 W  
PLM12 0.31513000 W

F2 - Processing parameters  
SI 131072  
SF 470.5923772 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00


(Z)-N'-(3-methoxyphenyl)benzimidamide (17) - <sup>1</sup>H NMR



<sup>13</sup>C NMR



(Z)-N'-(4-methoxy-3,5-dimethylphenyl)benzimidamide (**18**) - <sup>1</sup>H NMR




Current Data Parameters  
 NAME D321451  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20190714  
 Time 19:27 h  
 INSTRUM spect  
 PROBRD E122623\_0021 (  
 PULPROG zg30  
 TD 32564  
 SOLVENT CDCl3  
 NS 4  
 DS 2  
 SWH 8223.665 Hz  
 FIDRES 0.505078 Hz  
 AQ 1.9798912 sec  
 RG 128  
 DW 60.800 usec  
 DE 10.00 usec  
 TE 300.0 K  
 D1 2.0000000 sec  
 TD0 1  
 SFO1 400.1324710 MHz  
 NUC1 1H  
 P0 4.00 usec  
 P1 12.00 usec  
 PLW1 7.19999981 W

F2 - Processing parameters  
 SI 32768  
 SF 400.1300108 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

<sup>13</sup>C NMR




Current Data Parameters  
 NAME D321451  
 EXPNO 3  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20190714  
 Time 23:10 h  
 INSTRUM spect  
 PROBRD E122623\_0021 (  
 PULPROG zgpg30  
 TD 16384  
 SOLVENT CDCl3  
 NS 4096  
 DS 4  
 SWH 25252.525 Hz  
 FIDRES 3.082584 Hz  
 AQ 0.3244032 sec  
 RG 2050  
 DW 19.800 usec  
 DE 18.00 usec  
 TE 300.0 K  
 D1 2.0000000 sec  
 D11 0.0300000 sec  
 TD0 1  
 SFO1 100.6228298 MHz  
 NUC1 13C  
 P0 3.33 usec  
 P1 10.00 usec  
 PLW1 35.00000000 W  
 SFO2 400.1316005 MHz  
 NUC2 1H  
 CPDPRG[2] waltz16  
 PCPD2 90.00 usec  
 PLW2 7.50000000 W  
 PLW12 0.16379000 W  
 PLW13 0.08238400 W

F2 - Processing parameters  
 SI 32768  
 SF 100.6128153 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40


(Z)-N'-(3,4,5-trifluorophenyl)benzimidamide (**19**) - <sup>1</sup>H NMR




<sup>13</sup>C NMR



<sup>19</sup>F NMR




(Z)-N'-(E-styryl)benzimidamide (20) - <sup>1</sup>H NMR







<sup>13</sup>C NMR




(Z)-N'-(cyclohex-1-en-1-yl)benzimidamide (21) - <sup>1</sup>H NMR



<sup>13</sup>C NMR




(Z)-4-chloro-N'-phenylbenzimidamide (24) - <sup>1</sup>H NMR





<sup>13</sup>C NMR




Current Data Parameters  
NAME JR0281-D316653  
EXPNO 2  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190407  
Time 1.17 h  
INSTRUM spect  
PROBHD Z122623\_0021 (   
PULPROG zgpg30  
TD 16384  
SOLVENT CDCl3  
NS 8192  
DS 4  
SWH 25252.525 Hz  
FIDRES 3.082584 Hz  
AQ 0.3244032 sec  
RG 2050  
DW 19.800 usec  
DE 18.00 usec  
TE 300.0 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SFO1 100.6228298 MHz  
NUC1 13C  
PO 3.33 usec  
P1 10.00 usec  
PLW1 35.00000000 W  
SFO2 400.1316005 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 7.50000000 W  
PLW12 0.16379000 W  
PLW13 0.08238400 W

F2 - Processing parameters  
SI 32768  
SF 100.6128193 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

(Z)-2-fluoro-N'-phenylbenzimidamide (26) - <sup>1</sup>H NMR




Current Data Parameters  
NAME JR0288-D317092  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190416  
Time 17.40 h  
INSTRUM spect  
PROBHD Z122623\_0021 (   
PULPROG zg30  
TD 32564  
SOLVENT CDCl3  
NS 4  
DS 2  
SWH 8223.685 Hz  
FIDRES 0.505078 Hz  
AQ 1.9798912 sec  
RG 57  
DW 60.800 usec  
DE 10.00 usec  
TE 300.0 K  
D1 2.00000000 sec  
TD0 1  
SFO1 400.1324710 MHz  
NUC1 1H  
PO 4.00 usec  
P1 12.00 usec  
PLW1 7.19959981 W

F2 - Processing parameters  
SI 32768  
SF 400.1300105 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

<sup>13</sup>C NMR




Current Data Parameters  
NAME JR0288-D317092  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190417  
Time 1.39 h  
INSTRUM spect  
PROBHD Z122623\_0021 ( )  
PULPROG zgpg30  
TD 16384  
SOLVENT CDCl3  
NS 8192  
DS 4  
SWH 28252.525 Hz  
FIDRES 3.082584 Hz  
AQ 0.3244032 sec  
RG 2050  
DW 19.800 usec  
DE 18.00 usec  
TE 300.0 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SFO1 100.6228298 MHz  
NUC1 13C  
FO 3.33 usec  
P1 10.00 usec  
PLW1 35.00000000 W  
SFO2 400.1316005 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 7.50000000 W  
PLW12 0.16379000 W  
PLW13 0.08238400 W

F2 - Processing parameters  
SI 32768  
SF 100.6128193 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

<sup>19</sup>F NMR




Current Data Parameters  
NAME JR0288-D317092  
EXPNO 2  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20190416  
Time 17.44 h  
INSTRUM spect  
PROBHD Z122623\_0021 ( )  
PULPROG zg30  
TD 261896  
SOLVENT CDCl3  
NS 32  
DS 4  
SWH 89285.711 Hz  
FIDRES 0.681841 Hz  
AQ 1.4666176 sec  
RG 16  
DW 5.600 usec  
DE 18.37 usec  
TE 300.0 K  
D1 2.00000000 sec  
TD0 1  
SFO1 376.4607162 MHz  
NUC1 19F  
FO 5.00 usec  
P1 15.00 usec  
PLW1 5.19999981 W

F2 - Processing parameters  
SI 262144  
SF 376.4983660 MHz  
WDW EM  
SSB 0  
LB 0.50 Hz  
GB 0  
PC 1.00


(Z)-3-bromo-N'-phenylbenzimidamide (27) - <sup>1</sup>H NMR




<sup>13</sup>C NMR




(Z)-4-methyl-N'-phenylbenzimidamide (**28**) - <sup>1</sup>H NMR




<sup>13</sup>C NMR



(Z)-3-cyano-N'-phenylbenzimidamide (**29**) - <sup>1</sup>H NMR




<sup>13</sup>C NMR







(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-phenylbenzimidamide (**30**) - <sup>1</sup>H NMR



<sup>13</sup>C NMR



<sup>19</sup>F NMR




-73.82





Current Data Parameters  
NAME JR0305-D322176  
EXPNO 2  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190803  
Time 15.54 h  
INSTRUM spect  
PROBHD Z122623\_0021 ( (   
PULPROG zg30  
TD 261896  
SOLVENT DMSO  
NS 32  
DS 4  
SWH 89285.711 Hz  
FIDRES 0.681841 Hz  
AQ 1.4666176 sec  
RG 16  
DW 5.600 usec  
DE 18.37 usec  
TE 300.0 K  
D1 2.00000000 sec  
TDO 1  
SFO1 376.4607162 MHz  
NUC1 19F  
PO 5.00 usec  
P1 15.00 usec  
PLW1 5.19999981 W

F2 - Processing parameters  
SI 262144  
SF 376.4983660 MHz  
WDW EM  
SSB 0  
LB 0.50 Hz  
GB 0  
PC 1.00




(Z)-N'-([1,1'-biphenyl]-4-yl)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)benzimidamide (**31**) - <sup>1</sup>H NMR




Current Data Parameters  
NAME JR0323-E42944  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190719  
Time 16.23 h  
INSTRUM spect  
PROBHD Z113652\_0211 (   
PULPROG zg30  
TD 39578  
SOLVENT DMSO  
NS 16  
DS 2  
SWH 10000.000 Hz  
FIDRES 0.505331 Hz  
AQ 1.9789000 sec  
RG 175.12  
DW 50.000 usec  
DE 6.50 usec  
TE 300.0 K  
D1 2.00000000 sec  
TDO 1  
SFO1 500.1330885 MHz  
NUC1 1H  
PO 3.55 usec  
P1 10.58 usec  
PLW1 20.00000000 W


F2 - Processing parameters  
SI 65536  
SF 500.1300000 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00




# <sup>13</sup>C NMR




# <sup>19</sup>F NMR





(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(4-(trifluoromethyl)phenyl)benzimidamide (32) - <sup>1</sup>H NMR



<sup>13</sup>C NMR



<sup>19</sup>F NMR





Current Data Parameters  
NAME JR0327-E43204  
EXPNO 2  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190805  
Time 11.39 h  
INSTRUM spect  
PROBHD Z113652\_0211 ( )  
PULPROG zgfglqn  
TD 130892  
SOLVENT DMSO  
NS 32  
DS 4  
SWH 113636.367 Hz  
FIDRES 1.736338 Hz  
AQ 0.5759248 sec  
RG 198.22  
DW 4.400 usec  
DE 6.50 usec  
TE 300.0 K  
D1 1.00000000 sec  
TD0 1  
SFO1 470.5453180 MHz  
NUC1 19F  
P1 15.00 usec  
PLW1 35.00000000 W

F2 - Processing parameters  
SI 65536  
SF 470.5923772 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N<sup>1</sup>-(4-(dimethylamino)phenyl)benzimidamide (**33**) - <sup>1</sup>H NMR




Current Data Parameters  
NAME JR0390-D332945  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20200314  
Time 17.21 h  
INSTRUM spect  
PROBHD Z122623\_0021 ( )  
PULPROG zg30  
TD 32584  
SOLVENT DMSO  
NS 32  
DS 2  
SWH 8223.685 Hz  
FIDRES 0.505078 Hz  
AQ 1.9798912 sec  
RG 114  
DW 60.800 usec  
DE 10.00 usec  
TE 300.0 K  
D1 2.00000000 sec  
TD0 1  
SFO1 400.1324710 MHz  
NUC1 1H  
PC 4.00 usec  
P1 12.00 usec  
PLW1 7.19999981 W

F2 - Processing parameters  
SI 32768  
SF 400.1300000 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

<sup>13</sup>C NMR




Current Data Parameters  
 NAME JR0390-D332945  
 EXPNO 3  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20200315  
 Time 2.12 h  
 INSTRUM spect  
 PROBHD Z122623\_0021 {  
 PULPROG zgpg30  
 TD 16384  
 SOLVENT DMSO  
 NS 4  
 DS 8192  
 SWH 25252.525 Hz  
 FIDRES 3.082584 Hz  
 AQ 0.3244032 sec  
 RG 2050  
 DW 19.800 usec  
 DE 18.00 usec  
 TE 300.0 K  
 D1 2.00000000 sec  
 D11 0.03000000 sec  
 TD0 1  
 SFO1 100.6228298 MHz  
 NUC1 13C  
 PO 3.33 usec  
 P1 10.00 usec  
 PLW1 35.00000000 W  
 SFO2 400.1316005 MHz  
 NUC2 1H  
 CPDPRG2 waltz16  
 PCPD2 90.00 usec  
 PLW2 7.50000000 W  
 PLW12 0.16379000 W  
 PLW13 0.08238400 W

F2 - Processing parameters  
 SI 32768  
 SF 100.6128193 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40

<sup>19</sup>F NMR




Current Data Parameters  
 NAME JR0390 Fluorine - E47338  
 EXPNO 1  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20200807  
 Time 12.52 h  
 INSTRUM spect  
 PROBHD Z113652\_0211 {  
 PULPROG zgflnpgn.2  
 TD 131072  
 SOLVENT DMSO  
 NS 16  
 DS 4  
 SWH 113636.367 Hz  
 FIDRES 1.733953 Hz  
 AQ 0.5767168 sec  
 RG 198.22  
 DW 4.400 usec  
 DE 6.50 usec  
 TE 300.0 K  
 D1 1.00000000 sec  
 D11 0.03000000 sec  
 D12 0.00002000 sec  
 TD0 1  
 SFO1 470.5452180 MHz  
 NUC1 19F  
 P1 15.00 usec  
 PLW1 35.00000000 W  
 SFO2 500.1320005 MHz  
 NUC2 1H  
 CPDPRG2 waltz16  
 PCPD2 80.00 usec  
 PLW2 21.00000000 W  
 PLW12 0.31513000 W

F2 - Processing parameters  
 SI 131072  
 SF 470.5923772 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00


(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(3-fluoro-4-methoxyphenyl)benzimidamide (**34**) - <sup>1</sup>H NMR




<sup>13</sup>C NMR



<sup>19</sup>F NMR




(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(quinolin-3-yl)benzimidamide (35) - <sup>1</sup>H NMR





# <sup>13</sup>C NMR




Current Data Parameters  
NAME JR0324-D321850  
EXPNO 4  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20190724  
Time 2.48 h  
INSTRUM spect  
PROBHD z122623\_0021 ( )  
PULPROG zgpg30  
TD 16384  
SOLVENT DMSO  
NS 4096  
DS 4  
SWH 25252.525 Hz  
FIDRES 3.082584 Hz  
AQ 0.3244032 sec  
RG 2050  
DN 19.800 usec  
DE 18.00 usec  
TE 300.0 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TDO 1  
SFO1 100.6228298 MHz  
NUC1 13C  
FO 3.33 usec  
P1 10.00 usec  
PLW1 35.0000000 W  
SFO2 400.1316005 MHz  
NUC2 1H  
CPDPRG2 waltz16  
PCPD2 90.00 usec  
PLW2 7.5000000 W  
PLW12 0.1637900 W  
PLW13 0.0823840 W

F2 - Processing parameters  
SI 32768  
SF 100.6126193 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

# <sup>19</sup>F NMR




Current Data Parameters  
NAME JR0324-D321850  
EXPNO 2  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20190723  
Time 19.04 h  
INSTRUM spect  
PROBHD z122623\_0021 ( )  
PULPROG zg30  
TD 261896  
SOLVENT DMSO  
NS 32  
DS 4  
SNH 89285.711 Hz  
FIDRES 0.681841 Hz  
AQ 1.4666176 sec  
RG 16  
DN 5.600 usec  
DE 18.37 usec  
TE 300.0 K  
D1 2.0000000 sec  
TDO 1  
SFO1 376.4607162 MHz  
NUC1 19F  
FO 5.00 usec  
P1 15.00 usec  
PLW1 5.19999981 W

F2 - Processing parameters  
SI 262144  
SF 376.4983660 MHz  
WDW EM  
SSB 0  
LB 0.50 Hz  
GB 0  
PC 1.00



(Z)-4-((5-(4-carbamimidoylphenoxy)pentyl)oxy)-N'-(3-((5-(dimethylamino)naphthalene)-1-sulfonamido)phenyl)benzimidamidem (**36**) - <sup>1</sup>H NMR



<sup>13</sup>C NMR



<sup>19</sup>F NMR



Current Data Parameters  
NAME JR0440-D337424  
EXPNO 2  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20201207  
Time 18.16 h  
INSTRUM spect  
PROBHD Z122623\_0021 (   
PULPROG zg30  
TD 261896  
SOLVENT DMSO  
NS 32  
DS 4  
SWH 89285.711 Hz  
FIDRES 0.681841 Hz  
AQ 1.4666176 sec  
RG 20.2  
DM 5.600 usec  
DE 18.37 usec  
TE 300.0 K  
D1 2.00000000 sec  
TD0 1  
SFO1 376.4607162 MHz  
NUC1 19F  
PO 5.00 usec  
P1 15.00 usec  
PLW1 5.19999981 W

F2 - Processing parameters  
SI 262144  
SF 376.4983660 MHz  
WDW EM  
SSB 0  
LB 0.50 Hz  
GB 0  
PC 1.00

## Crystallographic data tables

### Complex 4

**Table S8.** Crystal data and structure refinement for complex 4.

Empirical formula	C <sub>15</sub> H <sub>16</sub> CuN <sub>4</sub> O <sub>3</sub>	
Formula weight	363.86	
Temperature	123(2) K	
Wavelength	1.54184 Å	
Crystal system	Orthorhombic	
Space group	P 2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>	
Unit cell dimensions	a = 9.9702(5) Å	α = 90°.
	b = 11.3577(4) Å	β = 90°.
	c = 13.1156(5) Å	γ = 90°.
Volume	1485.19(11) Å <sup>3</sup>	
Z	4	
Density (calculated)	1.627 Mg/m <sup>3</sup>	
Absorption coefficient	2.271 mm <sup>-1</sup>	
F(000)	748	
Crystal size	0.40 x 0.08 x 0.03 mm <sup>3</sup>	
Theta range for data collection	5.151 to 73.200°.	
Index ranges	-12 ≤ h ≤ 11, -7 ≤ k ≤ 13, -15 ≤ l ≤ 16	
Reflections collected	5091	
Independent reflections	2919 [R(int) = 0.0301]	
Completeness to theta = 70.000°	100.0 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	1.00000 and 0.22234	
Refinement method	Full-matrix least-squares on F <sup>2</sup>	
Data / restraints / parameters	2919 / 4 / 230	
Goodness-of-fit on F <sup>2</sup>	1.030	
Final R indices [I > 2σ(I)]	R1 = 0.0337, wR2 = 0.0886	
R indices (all data)	R1 = 0.0360, wR2 = 0.0908	
Absolute structure parameter	-0.05(2)	
Extinction coefficient	n/a	
Largest diff. peak and hole	0.471 and -0.286 e.Å <sup>-3</sup>	

**Table S9.** Atomic coordinates ( $\times 10^4$ ) and equivalent isotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for complex **4**.  $U(\text{eq})$  is defined as one third of the trace of the orthogonalized  $U^{ij}$  tensor.

	x	y	z	$U(\text{eq})$
Cu(1)	1414(1)	85(1)	3900(1)	15(1)
O(1)	1043(3)	1082(2)	2701(2)	16(1)
O(2)	1353(3)	-815(2)	2613(2)	17(1)
O(3)	903(3)	187(2)	1176(2)	19(1)
N(1)	1264(4)	1237(2)	4984(2)	18(1)
N(2)	163(4)	2737(3)	4191(3)	21(1)
N(3)	1928(3)	-1217(3)	4780(2)	16(1)
N(4)	618(4)	-2638(3)	4024(3)	24(1)
C(1)	659(4)	2263(3)	5031(3)	15(1)
C(2)	481(3)	2899(3)	6019(3)	15(1)
C(3)	-276(4)	3937(3)	6063(3)	20(1)
C(4)	-420(4)	4547(4)	6973(3)	23(1)
C(5)	177(4)	4121(4)	7853(3)	24(1)
C(6)	928(4)	3100(3)	7816(3)	24(1)
C(7)	1086(4)	2501(3)	6902(3)	20(1)
C(8)	1517(4)	-2306(3)	4715(3)	15(1)
C(9)	2058(4)	-3256(3)	5395(3)	18(1)
C(10)	2296(4)	-3030(4)	6422(3)	21(1)
C(11)	2817(4)	-3913(4)	7029(4)	29(1)
C(12)	3132(4)	-4998(4)	6630(4)	31(1)
C(13)	2909(4)	-5217(4)	5598(4)	29(1)
C(14)	2360(4)	-4345(3)	4991(3)	22(1)
C(15)	1090(3)	154(3)	2117(3)	16(1)

**Table S10.** Bond lengths [Å] and angles [°] for complex **4**.

---

Cu(1)-N(1)	1.938(3)
Cu(1)-N(3)	1.945(3)
Cu(1)-O(1)	1.973(3)
Cu(1)-O(2)	1.974(2)
Cu(1)-C(15)	2.362(4)
O(1)-C(15)	1.304(4)
O(2)-C(15)	1.305(4)
O(3)-C(15)	1.249(4)
N(1)-C(1)	1.314(5)
N(1)-H(1N)	0.88(5)
N(2)-C(1)	1.322(5)
N(2)-H(2N)	0.874(14)
N(2)-H(3N)	0.884(14)
N(3)-C(8)	1.306(5)
N(3)-H(4N)	0.80(5)
N(4)-C(8)	1.329(5)
N(4)-H(5N)	0.869(14)
N(4)-H(6N)	0.874(14)
C(1)-C(2)	1.494(5)
C(2)-C(7)	1.382(5)
C(2)-C(3)	1.402(5)
C(3)-C(4)	1.388(5)
C(3)-H(3)	0.9500
C(4)-C(5)	1.386(6)
C(4)-H(4)	0.9500
C(5)-C(6)	1.382(6)
C(5)-H(5)	0.9500
C(6)-C(7)	1.387(5)
C(6)-H(6)	0.9500
C(7)-H(7)	0.9500
C(8)-C(9)	1.500(5)
C(9)-C(14)	1.379(5)
C(9)-C(10)	1.391(6)
C(10)-C(11)	1.382(6)
C(10)-H(10)	0.9500
C(11)-C(12)	1.376(7)

C(11)-H(11)	0.9500
C(12)-C(13)	1.393(7)
C(12)-H(12)	0.9500
C(13)-C(14)	1.384(6)
C(13)-H(13)	0.9500
C(14)-H(14)	0.9500
N(1)-Cu(1)-N(3)	95.64(13)
N(1)-Cu(1)-O(1)	100.52(11)
N(3)-Cu(1)-O(1)	163.55(12)
N(1)-Cu(1)-O(2)	167.01(12)
N(3)-Cu(1)-O(2)	97.01(12)
O(1)-Cu(1)-O(2)	67.04(10)
N(1)-Cu(1)-C(15)	133.90(13)
N(3)-Cu(1)-C(15)	130.46(13)
O(1)-Cu(1)-C(15)	33.51(11)
O(2)-Cu(1)-C(15)	33.53(11)
C(15)-O(1)-Cu(1)	89.8(2)
C(15)-O(2)-Cu(1)	89.8(2)
C(1)-N(1)-Cu(1)	132.0(3)
C(1)-N(1)-H(1N)	116(3)
Cu(1)-N(1)-H(1N)	112(3)
C(1)-N(2)-H(2N)	119(4)
C(1)-N(2)-H(3N)	124(4)
H(2N)-N(2)-H(3N)	117(5)
C(8)-N(3)-Cu(1)	126.8(3)
C(8)-N(3)-H(4N)	114(3)
Cu(1)-N(3)-H(4N)	118(3)
C(8)-N(4)-H(5N)	124(3)
C(8)-N(4)-H(6N)	125(4)
H(5N)-N(4)-H(6N)	109(4)
N(1)-C(1)-N(2)	119.6(4)
N(1)-C(1)-C(2)	121.6(3)
N(2)-C(1)-C(2)	118.8(3)
C(7)-C(2)-C(3)	118.4(4)
C(7)-C(2)-C(1)	121.1(3)
C(3)-C(2)-C(1)	120.4(4)
C(4)-C(3)-C(2)	120.8(4)

C(4)-C(3)-H(3)	119.6
C(2)-C(3)-H(3)	119.6
C(5)-C(4)-C(3)	119.9(4)
C(5)-C(4)-H(4)	120.1
C(3)-C(4)-H(4)	120.1
C(6)-C(5)-C(4)	119.7(4)
C(6)-C(5)-H(5)	120.1
C(4)-C(5)-H(5)	120.1
C(5)-C(6)-C(7)	120.3(4)
C(5)-C(6)-H(6)	119.9
C(7)-C(6)-H(6)	119.9
C(2)-C(7)-C(6)	121.0(4)
C(2)-C(7)-H(7)	119.5
C(6)-C(7)-H(7)	119.5
N(3)-C(8)-N(4)	121.6(3)
N(3)-C(8)-C(9)	122.0(3)
N(4)-C(8)-C(9)	116.4(3)
C(14)-C(9)-C(10)	120.1(4)
C(14)-C(9)-C(8)	119.7(4)
C(10)-C(9)-C(8)	120.3(4)
C(11)-C(10)-C(9)	119.2(4)
C(11)-C(10)-H(10)	120.4
C(9)-C(10)-H(10)	120.4
C(12)-C(11)-C(10)	121.1(4)
C(12)-C(11)-H(11)	119.5
C(10)-C(11)-H(11)	119.5
C(11)-C(12)-C(13)	119.5(4)
C(11)-C(12)-H(12)	120.2
C(13)-C(12)-H(12)	120.2
C(14)-C(13)-C(12)	119.7(4)
C(14)-C(13)-H(13)	120.2
C(12)-C(13)-H(13)	120.2
C(9)-C(14)-C(13)	120.4(4)
C(9)-C(14)-H(14)	119.8
C(13)-C(14)-H(14)	119.8
O(3)-C(15)-O(1)	123.4(3)
O(3)-C(15)-O(2)	123.2(3)
O(1)-C(15)-O(2)	113.3(3)



O(3)-C(15)-Cu(1)	179.3(3)
O(1)-C(15)-Cu(1)	56.65(17)
O(2)-C(15)-Cu(1)	56.69(17)

---

Symmetry transformations used to generate equivalent atoms:

**Table S11.** Anisotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for complex **4**. The anisotropic displacement factor exponent takes the form:  $-2\pi^2 [h^2 a^{*2} U^{11} + \dots + 2 h k a^* b^* U^{12}]$

	$U^{11}$	$U^{22}$	$U^{33}$	$U^{23}$	$U^{13}$	$U^{12}$
Cu(1)	20(1)	10(1)	14(1)	0(1)	-2(1)	1(1)
O(1)	24(1)	11(1)	15(1)	1(1)	-1(1)	1(1)
O(2)	25(1)	10(1)	16(1)	-2(1)	-1(1)	2(1)
O(3)	27(1)	15(1)	15(1)	0(1)	1(1)	-3(1)
N(1)	27(2)	12(1)	13(1)	-2(1)	-1(2)	3(1)
N(2)	34(2)	14(2)	15(2)	-1(1)	0(1)	7(1)
N(3)	22(2)	12(1)	16(2)	3(1)	-6(1)	1(1)
N(4)	30(2)	16(2)	26(2)	7(1)	-10(2)	-6(1)
C(1)	18(2)	10(2)	17(2)	1(1)	-1(2)	-4(1)
C(2)	17(2)	12(2)	18(2)	0(1)	2(2)	-4(1)
C(3)	19(2)	18(2)	23(2)	1(2)	-3(2)	5(1)
C(4)	19(2)	24(2)	25(2)	-8(2)	3(2)	5(2)
C(5)	25(2)	26(2)	21(2)	-7(2)	3(2)	-5(2)
C(6)	33(2)	24(2)	16(2)	3(2)	-3(2)	-4(2)
C(7)	28(2)	12(2)	21(2)	0(1)	1(2)	0(1)
C(8)	17(2)	12(2)	16(2)	0(1)	0(2)	3(1)
C(9)	14(2)	16(2)	22(2)	6(2)	-3(2)	-3(1)
C(10)	18(2)	18(2)	26(2)	3(1)	-3(2)	-5(1)
C(11)	23(2)	35(2)	29(2)	12(2)	-10(2)	-9(2)
C(12)	17(2)	28(2)	47(2)	23(2)	-7(2)	-4(2)
C(13)	20(2)	15(2)	53(3)	9(2)	4(2)	2(1)
C(14)	22(2)	16(2)	30(2)	4(2)	6(2)	0(1)
C(15)	15(1)	12(2)	20(2)	1(1)	2(1)	-2(1)

**Table S12.** Hydrogen coordinates ( $\times 10^4$ ) and isotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for complex **4**.

	x	y	z	U(eq)
H(1N)	1650(50)	1000(40)	5560(30)	21
H(4N)	2530(50)	-1120(40)	5170(40)	20
H(3)	-696	4227	5463	24
H(4)	-926	5255	6993	27
H(5)	71	4530	8480	29
H(6)	1338	2806	8418	29
H(7)	1617	1807	6883	24
H(10)	2102	-2278	6702	25
H(11)	2960	-3768	7734	35
H(12)	3499	-5594	7054	37
H(13)	3134	-5960	5314	35
H(14)	2190	-4498	4290	27
H(2N)	310(60)	2390(40)	3610(20)	41(16)
H(3N)	-220(60)	3440(30)	4170(40)	49(17)
H(5N)	280(40)	-2170(30)	3570(30)	18(12)
H(6N)	160(50)	-3290(30)	4040(40)	40(15)

**Table S13.** Torsion angles [°] for complex **4**.

---

Cu(1)-N(1)-C(1)-N(2)	-9.3(6)
Cu(1)-N(1)-C(1)-C(2)	168.8(3)
N(1)-C(1)-C(2)-C(7)	7.9(5)
N(2)-C(1)-C(2)-C(7)	-173.9(3)
N(1)-C(1)-C(2)-C(3)	-174.0(4)
N(2)-C(1)-C(2)-C(3)	4.2(5)
C(7)-C(2)-C(3)-C(4)	-0.3(5)
C(1)-C(2)-C(3)-C(4)	-178.4(3)
C(2)-C(3)-C(4)-C(5)	-0.7(6)
C(3)-C(4)-C(5)-C(6)	0.9(6)
C(4)-C(5)-C(6)-C(7)	0.0(6)
C(3)-C(2)-C(7)-C(6)	1.3(6)
C(1)-C(2)-C(7)-C(6)	179.4(3)
C(5)-C(6)-C(7)-C(2)	-1.1(6)
Cu(1)-N(3)-C(8)-N(4)	-2.7(6)
Cu(1)-N(3)-C(8)-C(9)	175.7(3)
N(3)-C(8)-C(9)-C(14)	-137.6(4)
N(4)-C(8)-C(9)-C(14)	40.9(5)
N(3)-C(8)-C(9)-C(10)	40.3(5)
N(4)-C(8)-C(9)-C(10)	-141.2(4)
C(14)-C(9)-C(10)-C(11)	-0.9(6)
C(8)-C(9)-C(10)-C(11)	-178.9(3)
C(9)-C(10)-C(11)-C(12)	1.5(6)
C(10)-C(11)-C(12)-C(13)	-0.7(6)
C(11)-C(12)-C(13)-C(14)	-0.7(6)
C(10)-C(9)-C(14)-C(13)	-0.5(6)
C(8)-C(9)-C(14)-C(13)	177.4(3)
C(12)-C(13)-C(14)-C(9)	1.3(6)
Cu(1)-O(1)-C(15)-O(3)	179.1(3)
Cu(1)-O(1)-C(15)-O(2)	-1.0(3)
Cu(1)-O(2)-C(15)-O(3)	-179.1(3)
Cu(1)-O(2)-C(15)-O(1)	1.0(3)

---

Symmetry transformations used to generate equivalent atoms:

**Table S14.** Hydrogen bonds for complex **4** [ $\text{\AA}$  and  $^\circ$ ].

D-H...A	d(D-H)	d(H...A)	d(D...A)	<(DHA)
N(3)-H(4N)...O(3)#1	0.80(5)	2.30(5)	3.066(4)	161(4)
N(2)-H(2N)...O(1)	0.874(14)	2.04(3)	2.850(4)	154(5)
N(2)-H(3N)...O(3)#2	0.884(14)	2.146(18)	3.017(4)	168(5)
N(4)-H(5N)...O(2)	0.869(14)	2.26(4)	2.872(4)	128(4)
N(4)-H(6N)...O(3)#3	0.874(14)	2.045(16)	2.911(4)	171(5)

Symmetry transformations used to generate equivalent atoms:

#1  $-x+1/2, -y, z+1/2$  #2  $-x, y+1/2, -z+1/2$  #3  $-x, y-1/2, -z+1/2$

(*Z*)-*N'*-(4-(trifluoromethyl)phenyl)benzimidamide (**10**)

**Table S15.** Crystal data and structure refinement for **10**.

Identification code	bur_aug19	
Empirical formula	C <sub>14</sub> H <sub>11</sub> F <sub>3</sub> N <sub>2</sub>	
Formula weight	264.25	
Temperature	123(2) K	
Wavelength	1.54184 $\text{\AA}$	
Crystal system	Triclinic	
Space group	P -1	
Unit cell dimensions	a = 5.4166(7) $\text{\AA}$	$\alpha = 76.595(11)^\circ$ .
	b = 8.4710(11) $\text{\AA}$	$\beta = 84.634(11)^\circ$ .
	c = 13.9435(19) $\text{\AA}$	$\gamma = 86.123(11)^\circ$ .
Volume	618.93(14) $\text{\AA}^3$	
Z	2	
Density (calculated)	1.418 Mg/m <sup>3</sup>	
Absorption coefficient	1.004 mm <sup>-1</sup>	
F(000)	272	
Crystal size	0.40 x 0.20 x 0.10 mm <sup>3</sup>	
Theta range for data collection	5.623 to 69.996 $^\circ$ .	
Index ranges	$-6 \leq h \leq 4, -10 \leq k \leq 10, -16 \leq l \leq 16$	
Reflections collected	3917	
Independent reflections	2344 [R(int) = 0.0344]	
Completeness to theta = 69.996 $^\circ$	99.4 %	
Absorption correction	Semi-empirical from equivalents	
Max. and min. transmission	1.00000 and 0.30576	

Refinement method	Full-matrix least-squares on $F^2$
Data / restraints / parameters	2344 / 0 / 180
Goodness-of-fit on $F^2$	1.044
Final R indices [ $I > 2\sigma(I)$ ]	R1 = 0.0601, wR2 = 0.1651
R indices (all data)	R1 = 0.0750, wR2 = 0.1850
Extinction coefficient	n/a
Largest diff. peak and hole	0.381 and -0.318 e.Å <sup>-3</sup>

**Table S16.** Atomic coordinates ( $\times 10^4$ ) and equivalent isotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for **10**.  $U(\text{eq})$  is defined as one third of the trace of the orthogonalized  $U^{ij}$  tensor.

	x	y	z	U(eq)
F(1)	6528(5)	960(2)	557(1)	82(1)
F(2)	7395(5)	3427(3)	308(2)	88(1)
F(3)	3805(5)	2860(4)	120(2)	100(1)
N(1)	3415(3)	2582(2)	4737(2)	35(1)
N(2)	-897(4)	2437(3)	4734(2)	45(1)
C(1)	5600(6)	2390(4)	697(2)	52(1)
C(2)	4898(5)	2386(3)	1754(2)	40(1)
C(3)	3361(5)	3641(3)	1995(2)	42(1)
C(4)	2818(4)	3707(3)	2974(2)	39(1)
C(5)	3774(4)	2516(3)	3730(2)	34(1)
C(6)	5291(4)	1251(3)	3478(2)	36(1)
C(7)	5858(4)	1193(3)	2498(2)	39(1)
C(8)	1184(4)	2575(3)	5161(2)	35(1)
C(9)	865(4)	2607(3)	6228(2)	35(1)
C(10)	-1061(4)	1825(3)	6850(2)	39(1)
C(11)	-1262(5)	1781(3)	7854(2)	42(1)
C(12)	468(5)	2525(3)	8248(2)	43(1)
C(13)	2373(5)	3329(3)	7633(2)	42(1)
C(14)	2596(4)	3369(3)	6627(2)	38(1)

**Table S17.** Bond lengths [Å] and angles [°] for **10**.

---

F(1)-C(1)	1.330(3)
F(2)-C(1)	1.344(4)
F(3)-C(1)	1.302(4)
N(1)-C(8)	1.294(3)
N(1)-C(5)	1.413(3)
N(2)-C(8)	1.347(3)
N(2)-H(1N)	0.86(3)
N(2)-H(2N)	0.88(3)
C(1)-C(2)	1.488(4)
C(2)-C(7)	1.382(4)
C(2)-C(3)	1.389(4)
C(3)-C(4)	1.383(4)
C(3)-H(3)	0.9500
C(4)-C(5)	1.391(3)
C(4)-H(4)	0.9500
C(5)-C(6)	1.396(3)
C(6)-C(7)	1.384(3)
C(6)-H(6)	0.9500
C(7)-H(7)	0.9500
C(8)-C(9)	1.489(3)
C(9)-C(10)	1.392(3)
C(9)-C(14)	1.397(3)
C(10)-C(11)	1.386(4)
C(10)-H(10)	0.9500
C(11)-C(12)	1.383(4)
C(11)-H(11)	0.9500
C(12)-C(13)	1.386(4)
C(12)-H(12)	0.9500
C(13)-C(14)	1.389(4)
C(13)-H(13)	0.9500
C(14)-H(14)	0.9500
C(8)-N(1)-C(5)	119.31(19)
C(8)-N(2)-H(1N)	121.6(19)
C(8)-N(2)-H(2N)	118(2)
H(1N)-N(2)-H(2N)	118(3)



F(3)-C(1)-F(1)	108.0(3)
F(3)-C(1)-F(2)	104.2(3)
F(1)-C(1)-F(2)	104.6(3)
F(3)-C(1)-C(2)	114.2(3)
F(1)-C(1)-C(2)	113.3(2)
F(2)-C(1)-C(2)	111.7(2)
C(7)-C(2)-C(3)	119.8(2)
C(7)-C(2)-C(1)	120.7(2)
C(3)-C(2)-C(1)	119.5(2)
C(4)-C(3)-C(2)	120.1(2)
C(4)-C(3)-H(3)	120.0
C(2)-C(3)-H(3)	120.0
C(3)-C(4)-C(5)	120.8(2)
C(3)-C(4)-H(4)	119.6
C(5)-C(4)-H(4)	119.6
C(4)-C(5)-C(6)	118.5(2)
C(4)-C(5)-N(1)	123.1(2)
C(6)-C(5)-N(1)	118.3(2)
C(7)-C(6)-C(5)	120.8(2)
C(7)-C(6)-H(6)	119.6
C(5)-C(6)-H(6)	119.6
C(2)-C(7)-C(6)	120.1(2)
C(2)-C(7)-H(7)	120.0
C(6)-C(7)-H(7)	120.0
N(1)-C(8)-N(2)	125.5(2)
N(1)-C(8)-C(9)	118.2(2)
N(2)-C(8)-C(9)	116.2(2)
C(10)-C(9)-C(14)	119.1(2)
C(10)-C(9)-C(8)	121.3(2)
C(14)-C(9)-C(8)	119.6(2)
C(11)-C(10)-C(9)	120.9(2)
C(11)-C(10)-H(10)	119.6
C(9)-C(10)-H(10)	119.6
C(12)-C(11)-C(10)	119.8(2)
C(12)-C(11)-H(11)	120.1
C(10)-C(11)-H(11)	120.1
C(11)-C(12)-C(13)	119.8(2)
C(11)-C(12)-H(12)	120.1

C(13)-C(12)-H(12)	120.1
C(12)-C(13)-C(14)	120.7(2)
C(12)-C(13)-H(13)	119.6
C(14)-C(13)-H(13)	119.6
C(13)-C(14)-C(9)	119.6(2)
C(13)-C(14)-H(14)	120.2
C(9)-C(14)-H(14)	120.2

---

Symmetry transformations used to generate equivalent atoms:

**Table S18.** Anisotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for **10**. The anisotropic displacement factor exponent takes the form:  $-2\pi^2 [ h^2 a^{*2} U^{11} + \dots + 2 h k a^* b^* U^{12} ]$

	$U^{11}$	$U^{22}$	$U^{33}$	$U^{23}$	$U^{13}$	$U^{12}$
F(1)	148(2)	49(1)	49(1)	-20(1)	5(1)	20(1)
F(2)	124(2)	81(2)	58(1)	-21(1)	32(1)	-30(1)
F(3)	105(2)	152(3)	52(1)	-43(1)	-29(1)	42(2)
N(1)	39(1)	30(1)	38(1)	-10(1)	-4(1)	-2(1)
N(2)	36(1)	61(1)	40(1)	-16(1)	-2(1)	-6(1)
C(1)	71(2)	41(1)	44(2)	-12(1)	-6(1)	8(1)
C(2)	47(1)	33(1)	42(1)	-13(1)	-4(1)	-3(1)
C(3)	54(1)	31(1)	38(1)	-4(1)	-6(1)	2(1)
C(4)	44(1)	29(1)	44(1)	-11(1)	-2(1)	3(1)
C(5)	35(1)	30(1)	40(1)	-11(1)	-5(1)	-6(1)
C(6)	40(1)	28(1)	41(1)	-7(1)	-6(1)	-3(1)
C(7)	44(1)	31(1)	45(1)	-13(1)	-3(1)	0(1)
C(8)	38(1)	25(1)	42(1)	-8(1)	-5(1)	-1(1)
C(9)	36(1)	27(1)	42(1)	-11(1)	-4(1)	4(1)
C(10)	41(1)	33(1)	44(1)	-11(1)	-6(1)	-1(1)
C(11)	42(1)	36(1)	46(1)	-7(1)	2(1)	-1(1)
C(12)	50(1)	42(1)	39(1)	-14(1)	-5(1)	9(1)
C(13)	44(1)	39(1)	46(1)	-17(1)	-10(1)	4(1)
C(14)	38(1)	33(1)	43(1)	-11(1)	-3(1)	0(1)

**Table S19.** Hydrogen coordinates ( $\times 10^4$ ) and isotropic displacement parameters ( $\text{\AA}^2 \times 10^3$ ) for **10**.

	x	y	z	U(eq)
H(3)	2681	4455	1485	50
H(4)	1781	4576	3132	47
H(6)	5941	419	3986	43
H(7)	6909	332	2336	47
H(10)	-2254	1313	6582	46
H(11)	-2584	1241	8270	50
H(12)	351	2485	8937	52
H(13)	3539	3858	7903	50
H(14)	3919	3912	6213	45
H(1N)	-2340(50)	2490(30)	5040(20)	38(7)
H(2N)	-800(50)	2530(40)	4090(30)	47(8)

**Table S20.** Torsion angles [°] for **10**.

---

F(3)-C(1)-C(2)-C(7)	143.4(3)
F(1)-C(1)-C(2)-C(7)	19.2(4)
F(2)-C(1)-C(2)-C(7)	-98.6(3)
F(3)-C(1)-C(2)-C(3)	-39.9(4)
F(1)-C(1)-C(2)-C(3)	-164.0(3)
F(2)-C(1)-C(2)-C(3)	78.1(3)
C(7)-C(2)-C(3)-C(4)	0.8(4)
C(1)-C(2)-C(3)-C(4)	-176.0(2)
C(2)-C(3)-C(4)-C(5)	-0.8(4)
C(3)-C(4)-C(5)-C(6)	-0.1(3)
C(3)-C(4)-C(5)-N(1)	175.6(2)
C(8)-N(1)-C(5)-C(4)	61.6(3)
C(8)-N(1)-C(5)-C(6)	-122.7(2)
C(4)-C(5)-C(6)-C(7)	0.8(3)
N(1)-C(5)-C(6)-C(7)	-175.11(19)
C(3)-C(2)-C(7)-C(6)	-0.1(4)
C(1)-C(2)-C(7)-C(6)	176.7(2)
C(5)-C(6)-C(7)-C(2)	-0.7(3)
C(5)-N(1)-C(8)-N(2)	3.1(3)
C(5)-N(1)-C(8)-C(9)	178.60(19)
N(1)-C(8)-C(9)-C(10)	-147.3(2)
N(2)-C(8)-C(9)-C(10)	28.6(3)
N(1)-C(8)-C(9)-C(14)	29.6(3)
N(2)-C(8)-C(9)-C(14)	-154.5(2)
C(14)-C(9)-C(10)-C(11)	-0.6(4)
C(8)-C(9)-C(10)-C(11)	176.3(2)
C(9)-C(10)-C(11)-C(12)	0.1(4)
C(10)-C(11)-C(12)-C(13)	0.9(4)
C(11)-C(12)-C(13)-C(14)	-1.3(4)
C(12)-C(13)-C(14)-C(9)	0.7(4)
C(10)-C(9)-C(14)-C(13)	0.2(3)
C(8)-C(9)-C(14)-C(13)	-176.7(2)

---

Symmetry transformations used to generate equivalent atoms:

**Table S21.** Hydrogen bonds for **10** [Å and °].

D-H...A	d(D-H)	d(H...A)	d(D...A)	<(DHA)
N(2)-H(1N)...N(1)#1	0.86(3)	2.37(3)	3.074(3)	140(2)

Symmetry transformations used to generate equivalent atoms:

#1 x-1,y,z

## References

- (1) Scala, A.; Piperno, A.; Micale, N.; Mineo, P. G.; Abbadessa, A.; Risoluti, R.; Castelli, G.; Bruno, F.; Vitale, F.; Cascio, A.; Grassi, G. “Click” on PLGA-PEG and Hyaluronic Acid: Gaining Access to Anti-Leishmanial Pentamidine Bioconjugates. *J. Biomed. Mater. Res. - Part B Appl. Biomater.* **2018**, *106*.
- (2) Nvau, J. B.; Alenezi, S.; Ungogo, M. A.; Alfayez, I. A. M.; Natto, M. J.; Gray, A. I.; Ferro, V. A.; Watson, D. G.; de Koning, H. P.; Igoli, J. O. Antiparasitic and Cytotoxic Activity of Bokkosin, A Novel Diterpene-Substituted Chromanyl Benzoquinone From *Calliandra Portoricensis*. *Front. Chem.* **2020**.
- (3) Carruthers, L. V.; Munday, J. C.; Ebiloma, G. U.; Steketee, P.; Jayaraman, S.; Campagnaro, G. D.; Ungogo, M. A.; Donachie, A. M.; Rowan, T. G.; Peter, R.; Morrison, L. J.; Barrett, M. P.; de Koning, H. P. Diminazene Resistance in *Trypanosoma Congolense* Is Linked to Reduced Mitochondrial Membrane Potential and Not to Reduced Transport Capacity. *bioRxiv.* **2020**.
- (4) Coustou, V.; Guegan, F.; Plazolles, N.; Baltz, T. Complete In Vitro Life Cycle of *Trypanosoma Congolense*: Development of Genetic Tools. *PLoS Negl. Trop. Dis.* **2010**, *4*, e618.
- (5) Al-Salabi, M. I.; Wallace, L. J. M.; De Koning, H. P. A *Leishmania* Major Nucleobase Transporter Responsible for Allopurinol Uptake Is a Functional Homolog of the *Trypanosoma Brucei* H2 Transporter. *Mol. Pharmacol.* **2003**, *63* (4), 814–820.
- (6) Cueto-Díaz, E. J.; Ebiloma, G. U.; Alfayez, I. A.; Ungogo, M. A.; Lemgruber, L.; González-García, M. C.; Giron, M. D.; Salto, R.; Fueyo-González, F. J.; Shiba, T.; González-Vera, J. A.; Ruedas Rama, M. J.; Orte, A.; de Koning, H. P.; Dardonville, C. Synthesis, Biological, and Photophysical Studies of Molecular Rotor-Based Fluorescent Inhibitors of the Trypanosome Alternative Oxidase. *Eur. J. Med. Chem.* **2021**, *220*, 113470.